UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 20192020

 

or

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number: 001-37899

 

SCWORX CORP.

(Exact name of registrant as specified in its charter)

 

Delaware47-5412331

(State or other jurisdiction of


incorporation or organization)

(I.R.S. Employer


Identification No.)

 

590 Madison Avenue, 21st21st Floor

New York, New York 10022

(Address of principal executive offices, including zip code)

 

(212) 739-7825(844) 472-9679

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each classTrading symbol(s)Symbol(s)Name of each exchange on which registered
Common stock, $0.001 par value per shareWORXNasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes   x     No   ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer¨Accelerated filer¨
Non-accelerated filerxSmaller reporting companyx
  Emerging growth companyx

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No    x

  

Number of shares of the registrant’s common stock outstanding at August 12, 2019: 6,584,1807, 2020: 9,490,582.

 

 

 

 

SCWorx Corp.

Form 10-Q

TABLE OF CONTENTS

 

  Page
   
PART I - FINANCIAL INFORMATION41
  
Item 1.Financial Statements (unaudited)41
   
 Condensed Consolidated Balance Sheetsconsolidated balance sheets as of June 30, 2019  (unaudited)2020 and December 31, 20182019 (audited)41
   
 Condensed Consolidated Statementsconsolidated statements of Operationsoperations for the three and six months ended June 30, 20192020 and 2018 (unaudited)201952
   
 Condensed Consolidated Statementconsolidated statements of Changeschanges in Stockholders’ Equity/(Deficit)stockholders’ equity for the three and six months ended June 30, 20192020 and 2018 (unaudited)201963
   
 Condensed Consolidated Statementsconsolidated statements of Cash Flowscash flows for the three and six months ended June 30, 20192020 and 2018 (unaudited)201984
   
 Notes to the Condensed Consolidated Financial Statementsunaudited condensed consolidated financial statements95
   
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations3122
   
Item 3.Quantitative and Qualitative Disclosures About Market Risk3628
   
Item 4.Controls and Procedures3629
   
PART II - OTHER INFORMATION3730
  
Item 1.Legal Proceedings3730
   
Item 1A.Risk Factors3731
   
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds3731
   
Item 3.Defaults Upon Senior Securities3831
   
Item 4.Mine Safety Disclosures3831
   
Item 5.Other Information3831
   
Item 6.Exhibits3932
   
Signatures4033
   
Exhibit Index4132

 

2

i

 

   

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q (this “Form 10-Q”), constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”),or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).or the Exchange Act. All statements other than statements of historical fact contained in this Form 10-Q are forward-looking statements. These statements, among other things, relate to our business strategy, goals and expectations concerning our future operations, prospects, plans and objectives of management. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, and similar terms and phrases are used to identify forward-looking statements in this Form 10-Q.presentation.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements in this Form 10-Q include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook and increased operating expenses.

 

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward looking statements as set forth under the heading, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.2019. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to our ability to:

 

·

integratereverse the recent decline in our revenue and optimize the operations from the acquisition of SCWorx Corp.; and

resume growing our revenue;
·grow
obtain additional financing in sufficient amounts or on acceptable terms when required;
reduce our dependence on third-party subcontractors to perform some of the revenueswork on our contracts;
mitigate the impact of new or changed laws, regulations or other industry standards that could adversely affect our ability to conduct our business;
mitigate the impact of the COVID-19 pandemic on our revenues;
adopt and contain themaster new technologies and adjust certain fixed costs relatedand expenses to adapt to our recently acquired Software as a Service (“SaaS”) business.industry’s and customers’ evolving demands; and
mitigate the impact of changes in general market, economic and political conditions in the United States and global economies or financial markets, including those resulting from natural or man-made disasters.

 

Although we believe that the expectations reflected in the forward-looking statements contained in this Form 10-Q are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. In light of inherent risks, uncertainties and assumptions, the future events and trends discussed in this Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, we are under no duty to update or revise any of such forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this Form 10-Q.

 

You should read this Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

All references to “SCWorx,” “we,” “us,” “our” or the “Company” mean SCWorx Corp., a Delaware corporation, and where appropriate, its wholly owned subsidiaries.

 

3

ii

 

 

PART I-FINANCIALI - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

SCWorx Corp.

Condensed Consolidated Balance Sheets

 

 June 30, December 31, 
 June 30,
2019
  December 31,
2018
  2020  2019 
 (Unaudited) 

(Audited)

(as adjusted)

  (Unaudited)   
ASSETS             
Current assets:             
Cash $1,334,366  $76,459  $334,500  $487,953 
Accounts receivable  1,161,233   520,692 
Interest receivable     121,350 
Accounts receivable - net of allowance of $311,266 and $344,412 as of June 30, 2020 and December 31, 2019, respectively  735,692   799,246 
Inventory  558,119   - 
Prepaid expenses and other assets  136,096      692,631   11,160 
Convertible notes receivable, at fair value     837,317 
Investment in warrants, at fair value     67,000 
Total current assets  2,631,695   1,622,818   2,320,942   1,298,359 
                
Fixed assets  113,003      85,683   105,199 
Goodwill  8,366,467   8,366,467 
Intangible assets  224,190      186,248   205,219 
Goodwill  8,466,282    
Due from shareholder     1,409,284 
TOTAL ASSETS $11,435,170  $3,032,102 
Other assets  -   17,561 
Total assets $10,959,340  $9,992,805 
          ��     
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)        
LIABILITIES AND STOCKHOLDERS’ EQUITY        
        
Current liabilities:                
Accounts payable and accrued liabilities  2,120,361  $855,759  $2,143,640  $2,010,556 
Contract liabilities  912,196  816,714   1,827,262   1,056,637 
Notes payable related party  192,446    
Equity financing  515,000   - 
Total current liabilities  3,225,003   1,672,473   4,485,902   3,067,193 
Notes payable - related party     1,591,491 
TOTAL LIABILITIES  3,225,003   3,263,964 
        
Long-term liabilities:        
Loan payable  293,972   - 
Total long-term liabilities  293,972   - 
        
Total liabilities  4,779,874   3,067,193 
                
Commitments and contingencies                
                
Stockholders’ Equity/(Deficit):        
Series A Convertible Preferred stock, $0.001 par value; 900,000 shares authorized; 819,138 and 0 shares issued and outstanding, respectively  819    
Common stock, $0.001 par value; 45,000,000 shares authorized; 6,584,180 and 5,838,149 shares issued and outstanding, respectively  6,584   5,838 
Stockholders’ equity:        
Series A convertible preferred stock, $0.001 par value; 900,000 shares authorized; 94,872 and 578,567 shares issued and outstanding, respectively  95   579 
Common stock, $0.001 par value; 45,000,000 shares authorized; 9,490,582 and 7,390,261 shares issued and outstanding, respectively  9,491   7,391 
Additional paid-in capital  17,895,657   1,244,273   23,863,806   19,712,115 
Accumulated deficit  (9,692,893)  (1,481,973)  (17,693,926)  (12,794,473)
TOTAL STOCKHOLDERS’ EQUITY/(DEFICIT)  8,210,167   (231,862)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY / (DEFICIT) $11,435,170  $3,032,102 
Total stockholders’ equity  6,179,466   6,925,612 
        
Total liabilities and stockholders’ equity $10,959,340  $9,992,805 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4


SCWorx Corp.

Condensed Consolidated Statements of Operations

(Unaudited)

 

 For the three months ended For the six months ended 
 Three Months Ended Six Months Ended  June 30,  June 30, 
 June 30,  June 30,  2020  2019  2020  2019 
 2019  2018  2019  2018          
Revenue $1,364,912  $812,060  $2,613,016  $1,598,164  $1,444,572  $1,364,912  $2,568,399  $2,613,016 
Cost of revenue  815,788  729,131  1,604,658  1,522,356
Gross profit  549,124   82,929   1,008,358   75,808 
                
Operating expenses:                                
Cost of revenues  950,334   1,293,738   1,783,534   2,264,947 
General and administrative  2,372,385   88,514   9,000,324   224,030   3,358,267   2,372,385   4,798,545   9,000,324 
Research and development  477,950      660,289    
Total operating expenses  2,850,335   88,514   9,660,613   224,030   4,308,601   3,666,123   6,582,079   11,265,271 
                
Loss from operations  (2,301,211)  (5,585)  (8,652,255)  (148,222)  (2,864,029)  (2,301,211)  (4,013,680)  (8,652,255)
                
Other income (expenses):                
Loss on settlement of accounts payable  (885,773)  -   (885,773)  - 
Interest expense  -   -   -   (23,720)
Other income        465,055      -   -   -   465,055 
Interest expense     (48,434)  (23,720)  (90,057)
Loss before taxes  (2,301,211)  (54,019)  (8,210,920)  (238,279)
Income tax expense (benefit)  195,000          
Total other income (expense)  (885,773)  -   (885,773)  441,335 
                
Net loss before income taxes  (3,749,802)  (2,301,211)  (4,899,453)  (8,210,920)
                
Provision for (benefit from) income taxes  -   195,000   -   - 
                
Net loss $(2,496,211) $(54,019) $(8,210,920) $(238,279) $(3,749,802) $(2,496,211) $(4,899,453) $(8,210,920)
Loss per share:                
Basic and diluted $(0.38) $(0.01) $(1.48) $(0.05)
Weighted average number of shares used in per share calculation, basic and diluted  6,572,742   4,476,013   5,538,558   4,476,013 
     ��          
Net loss per share, basic and diluted $(0.41) $(0.38) $(0.59) $(1.48)
                
Weighted average common shares outstanding, basic and diluted  9,069,792   6,572,742   8,319,142   5,538,558 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

SCWorx Corp.

Condensed Consolidated Statements of Changes Inin Stockholders’ Equity/(Deficit)Equity

(Unaudited)

  Preferred Stock  Common stock  Additional paid-in  Accumulated    
Three months ended June 30, 2020 Shares  $  Shares  $  capital  deficit  Total 
                      
Balances, March 31, 2020  511,067  $511   7,634,561  $7,636  $20,079,538  $(13,944,124) $6,143,561 
                           - 
Conversion of Series A Convertible Preferred Stock into common stock  (416,195)  (416)  1,095,251   1,095   (679)  -   - 
Settlement of Accounts Payable  -   -   284,567   285   1,757,905   -   1,758,190 
Shares issued in cashless exercise of warrants  -   -   347,189   347   (347)  -   - 
Shares issued in cashless exercise of options  -   -   57,534   57   (57)  -   - 
Warrants exercised for cash  -   -   7,000   7   38,563   -   38,570 
Shares issued to current and former employees and directors  -   -   64,480   64   1,988,883   -   1,988,947 
Net Loss  -   -   -   -   -   (3,749,802)  (3,749,802)
                             
Ending balance, June 30, 2020  94,872  $95   9,490,582  $9,491  $23,863,806  $(17,693,926) $6,179,466 

 

  Preferred Stock  Common Stock  Additional
Paid-in
  Accumulated  Total
Stockholders’/
Equity
 
Three Months Ended June 30, 2019  Shares  Amount  Shares  Amount  Capital  Deficit  (Deficit) 
Balance at March 31, 2019, as restated  816,638  816   6,563,195  6,563  17,525,614  (7,196,682) 10,336,311
Series A Convertible Preferred share issuance  2,500   3         24,997      25,000 
Exercise of warrants        1,184   1   6,524      6,525 
Settlement of disputed contractual claim        19,801   20   117,982      118,002 
Stock-based compensation              220,540      220,540 
Net loss                 (2,496,211)  (2,496,211)
Balance—June 30, 2019  819,138  819   6,584,180  6,584  17,895,657  (9,692,893) $8,210,167 
                             
  Preferred Stock  Common Stock  Additional
Paid-in
  Accumulated  Total
Stockholders’/
Equity
 
Six Months Ended June 30, 2019  Shares  Amount  Shares  Amount  Capital  Deficit  (Deficit) 
Balance at December 31, 2018, as restated    $   5,838,149  $5,838  1,244,273  (1,481,973) (231,862)
Surrender of common shares in settlement of due from stockholder balance        (574,991  (575)  (1,608,258)     (1,608,833)
Series A Convertible Preferred share issuance (Alliance MMA)  619,138   619               5,980,945 
Issuance of common stock        1,283,124   1,283   5,980,326      5,884,361 
Series A Convertible Preferred share issuance  10,000   10         99,990      100,000 
Conversion of notes payable - related party into Series A Convertible Preferred share issuance  190,000   190         1,899,810      1,900,000 
Exercise of warrants        11,075   11   67,537      67,548 
Settlement of disputed contractual claim        19,801   20   117,982      118,002 
Issuance of warrants in settlement of lease dispute              66,275      66,275 
Shares issued in cashless exercise of warrants        3,732   4   (4      
Stock-based compensation related to founder’s transfers of common shares to contractors              5,322,930      5,322,930 
Stock-based compensation related to employee and contractor equity awards        3,290   3   527,440      527,443 
Stock and warrant dividend              (1,705,722)    (1,705,722)
Net loss                 (8,210,920)  (8,210,920)
Balance—June 30, 2019  819,138  819   6,584,180  6,584  17,895,657  (9,692,893) $8,210,167 
  Preferred Stock  Common stock  Additional paid-in  Accumulated    
Six months ended June 30, 2020 Shares  $  Shares  $  capital  deficit  Total 
                      
Balances, January 1, 2020  578,567  $579   7,390,261  $7,391  $19,712,115  $(12,794,473) $6,925,612 
                             
Conversion of Series A Convertible Preferred Stock into common stock  (483,695)  (484)  1,272,884   1,273   (789)  -   - 
Settlement of Accounts Payable          284,567   285   1,757,905   -   1,758,190 
Shares issued in cashless exercise of warrants  -   -   347,189   347   (347)  -   - 
Shares issued in cashless exercise of options  -   -   57,534   57   (57)  -   - 
Warrants exercised for cash  -   -   7,000   7   38,563   -   38,570 
Shares issued to current and former employees and directors  -   -   131,147   131   2,356,416   -   2,356,547 
Net Loss  -   -   -   -   -   (4,899,453)  (4,899,453)
                             
Ending balance, June 30, 2020  94,872  $95   9,490,582  $9,491  $23,863,806  $(17,693,926) $6,179,466 

  Preferred Stock  Common stock  Additional paid-in  Accumulated    
Three months ended June 30, 2019 Shares  $  Shares  $  capital  deficit  Total 
                      
Balances, March 31, 2019  816,638  $816   6,563,195  $6,563  $17,525,614  $(7,196,682) $10,336,311 
                           - 
Series A Convertible Preferred share issuance  2,500   3   -   -   24,997   -   25,000 
Exercise of warrants  -   -   1,184   1   6,524   -   6,525 
Settlement of disputed contractual claim  -   -   19,801   20   117,982   -   118,002 
Stock-based compensation  -   -   -   -   220,540   -   220,540 
Net loss  -   -   -   -   -   (2,496,211)  (2,496,211)
                             
Ending balance, June 30, 2019  819,138  $819   6,584,180  $6,584  $17,895,657  $(9,692,893) $8,210,167 

  Preferred Stock  Common stock  Additional paid-in  Accumulated    
Six months ended June 30, 2019 Shares  $  Shares  $  capital  deficit  Total 
                      
Balances, January 1, 2019  -  $-   5,838,149  $5,838  $1,244,273  $(1,481,973) $(231,862)
                             
Surrender of common shares in settlement of due from stockholder balance  -   -   (574,991)  (575)  (1,608,258)  -   (1,608,833)
Series A Convertible Preferred share issuance (Alliance MMA)  619,138   619   -   -   5,980,326   -   5,980,945 
Issuance of common stock  -   -   1,283,124   1,283   5,883,078   -   5,884,361 
Series A Convertible Preferred share issuance  10,000   10   -   -   99,990   -   100,000 
Conversion of notes payable - related party into Series A Convertible Preferred share issuance  190,000   190   -   -   1,899,810   -   1,900,000 
Exercise of warrants  -   -   11,075   11   67,537   -   67,548 
Settlement of disputed contractual claim  -   -   19,801   20   117,982   -   118,002 
Issuance of warrants in settlement of lease dispute  -   -   -   -   66,275   -   66,275 
Shares issued in cashless exercise of warrants  -   -   3,732   4   (4)  -   - 
Stock-based compensation related to founder’s transfers of common shares to contractors  -   -   -   -   5,322,930   -   5,322,930 
Stock-based compensation related to employee and contractor equity awards  -   -   3,290   3   527,440   -   527,443 
Stock and warrant dividend  -   -   -   -   (1,705,722)  -   (1,705,722)
Net loss  -   -   -   -   -   (8,210,920)  (8,210,920)
                             
Ending balance, June 30, 2019  819,138  $819   6,584,180  $6,584  $17,895,657  $(9,692,893) $8,210,167 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

3

 

SCWorx Corp.

Condensed Consolidated Statements of Changes In Stockholders’ Equity/(Deficit)(continued)Cash Flows

(Unaudited)

  Membership  Members’  Preferred Stock  Common Stock  Additional
Paid-in
  Accumulated  Total
Stockholders’/
Members’
 
Three Months Ended June 30, 2018  Units  Deficit  Shares  Amount  Shares  Amount  Capital  Deficit  Deficit 
Balance—March 31, 2018  17,500  $(1,285,519)    $     $  $  $  $(1,285,519)
Net loss     (54,019)                    (54,019)
Balance June 30, 2018  17,500  $(1,339,538)    $     $  $  $  $(1,339,538)

  Membership  Members’  Preferred Stock  Common Stock  Additional
Paid-in
  Accumulated  Total
Stockholders’/
Members’
 
Six Months Ended June 30, 2018  Units  Deficit  Shares  Amount  Shares  Amount  Capital  Deficit  Deficit 
Balance—December 31, 2018  17,500  $(1,101,259)    $     $  $  $  $(1,101,259)
Net loss     (238,279)                    (238,279)
Balance June 30, 2018  17,500  $(1,339,538)    $     $  $  $  $(1,339,538)

 

  For the six months ended 
  June 30, 
  2020  2019 
       
Cash flows from operating activities:      
Net loss $(4,899,453) $(8,210,920)
         
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation  19,516   1,804 
Amortization of intangibles  18,971   15,810 
Stock-based compensation  2,356,547   5,850,373 
Loss on settlement of accounts payable  885,773   - 
Gain (loss) on change in fair value of warrant assets  -   (55,000)
Gain (loss) on change in fair value of convertible notes receivable  -   (531,405)
Changes in operating assets and liabilities:        
Accounts receivable  63,554   (640,541)
Inventory  (109,244)  - 
Prepaid expenses  (655,346)  (14,746)
Other assets  17,561   - 
Accounts payable and accrued liabilities  530,501   (452,579)
Contract liabilities  770,625   95,482 
Net cash used in operating activities  (1,000,995)  (3,941,722)
         
Cash flows from investing activities:        
Cash acquired in reverse acquisition  -   5,441,437 
Advances to shareholder  -   (199,549)
Purchase of convertible notes receivable - Alliance MMA  -   (215,000)
Purchase of fixed assets  -   (114,807)
Net cash provided by investing activities  -   4,912,081 
         
Cash flows from financing activities:        
Proceeds from loans payable  293,972   - 
Proceeds from equity financing  515,000   - 
Proceeds from notes payable - related party  -   120,000 
Proceeds from exercise of warrants  38,570   67,548 
Proceeds from preferred stock placement  -   100,000 
Net cash provided by financing activities  847,542   287,548 
         
Net (decrease) increase in cash  (153,453)  1,257,907 
         
Cash, beginning of period  487,953   76,459 
         
Cash, end of period $334,500  $1,334,366 
         
Supplemental disclosures of cash flow information:        
Cash paid for interest $-  $- 
Cash paid for income taxes $-  $- 
         
Non-cash investing and financing activities:        
Shares issued to current and former employees $2,356,547  $- 
Cashless exercise of warrant $347  $4 
Cashless exercise of options $57  $- 
Settlement of accounts payable with issuance of common stock $1,758,190  $- 
Shareholder advances for purchase of inventory $475,000  $- 
Issuance of warrant in settlement of vendor liability $-  $66,275 
Surrender of common stock in settlement of due from shareholder balance $-  $1,608,833 
Stock and warrant dividend $-  $1,705,722 
Warrants issued to company $-  $19,000 
Conversion of notes payable-related party and interest into Series A Convertible Preferred Stock $-  $1,900,000 
Issuance of preferred and common stock in connection with acquisition of Alliance MMA, net of cash $-  $6,424,054 
Settlement of disputed contractual claim with issuance of common stock $-  $118,002 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7


SCWorx Corp.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

  Six Months Ended
June 30,
 
  2019   2018 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $(8,210,920) $(238,279)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation  1,804    
Stock-based compensation  5,850,373    
Amortization of acquired intangibles  15,810    
Gain on change in fair value of warrant assets  (55,000)   
Gain on change in fair value of convertible notes receivable  (531,405)   
Changes in operating assets and liabilities:       
Accounts receivable  (640,541)  (153,270)
Prepaid expenses and other assets  (14,746)   
Accounts payable and accrued liabilities  (138,065)  760,828
Contract liabilities  95,482   265,852 
Net cash (used in) provided by operating activities of continuing operations  (3,627,208)  635,131
Net cash (used in) operating activities of discontinued operations  (314,514)   
Net cash (used in) provided by operating activities  (3,941,722)  635,131 
CASH FLOWS FROM INVESTING ACTIVITIES:        
Cash acquired in reverse acquisition  5,441,437    
Advances to shareholder  (199,549)  (767,670)
Advances on convertible notes receivable - Alliance MMA  (215,000)  (554,375
Purchases of fixed assets  (114,807)   
Net cash provided by (used in) investing activities  4,912,081  (1,322,045)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from notes payable - related party  120,000   855,600 
Proceeds from preferred stock placement  100,000   
Proceeds from exercise of warrants  67,548    
Net cash provided by financing activities  287,548   855,600 
NET INCREASE IN CASH  1,257,907   168,686
CASH - BEGINNING OF PERIOD  76,459   15,159 
CASH - END OF PERIOD $1,334,366  $183,845 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid for interest $  $ 
Cash paid for taxes $  $ 
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Settlement of disputed contractual claim with issuance of common stock $118,002  $ 
Issuance of warrant in settlement of vendor liability - discontinued operations $66,275  $ 
Cashless exercise of warrant $4  $ 
Surrender of common shares in settlement of due from shareholder balance $1,608,833  $ 
Stock and warrant dividend $1,705,722  $ 
Warrants issued to company 19,000  $ 
Conversion of notes payable-related party and interest into Series A Convertible Preferred Shares $1,900,000  $ 
Issuance of preferred and common stock in connection with acquisition of Alliance MMA, net of cash $6,423,869  $ 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Description of Business

 

Nature of Business

 

SCWorx, LLC (n/k/a SCW FL Corp.) (“SCW LLC”) was a privately held limited liability company which was organized in Florida on November 17, 2016. On December 31, 2017, SCW LLC acquired Primrose Solutions, LLC (“Primrose”), a Delaware limited liability company, which became its wholly-owned subsidiary and focused on developing functionality for the software now used and sold by SCWorx Corp. (the “Company” or “SCWorx”). The majority shareholdersinterest holders of Primrose were shareholdersinterest holders of SCW LLC and based upon Staff Accounting Bulletin (“SAB”) Topic 5G, the technology acquired has been accounted for at predecessor cost of $0. To facilitate the planned acquisition by Alliance MMA, Inc., a Delaware corporation (“Alliance”), on June 27, 2018, SCW LLC merged with and into a newly-formed entity, SCWorx Acquisition Corp., a Delaware corporation (“SCW Acquisition”), with SCW Acquisition being the surviving entity. Subsequently, on August 17, 2018, SCW Acquisition changed its name to SCWorx Corp. On November 30, 2018, the Company and certain shareholdersof its stockholders agreed to cancel 6,510 shares of common shares.stock. In June 2018, the Company began to collect subscriptions for common stock. From June to November 2018, the Company collected $1.25 million$1,250,000 in subscriptions and issued 3,125 shares of common stock to new third-party investors. In addition, on February 1, 2019, (i) SCWorx Corp. (f/k/a SCWorx Acquisition Corp.) changed its name to SCW FL Corp. (to allow Alliance to change its name to SCWorx Corp.) and (ii) Alliance acquired SCWorx Corp. (n/k/a SCW FL Corp.) in a stock- for- stockstock-for-stock exchange transaction and changed Alliance’s name to SCWorx Corp., which is the Company’s current name, with SCW FL Corp. becoming the Company’s subsidiary. On March 16, 2020, in response to the COVID-19 pandemic, SCWorx established a wholly-owned subsidiary, Direct-Worx, LLC.

 

Business Combination and Related Transactions

In June 2018, SCWorx Acquisition Corp. entered into a Securities Purchase Agreement (“SPA”) with Alliance, as amended December 18, 2018, under which the SCWorx Acquisition Corp. agreed to purchase up to $1.25 million in principal amount of Alliance’s convertible notes and warrants to purchase up to 1,128,356 [59,387 shares reflective of one for nineteen stock split] [bracketed amounts disclosed represent post-split adjusted shares or per share amounts] shares of Alliance common stock. The initial $750,000 tranche of the notes was convertible into shares of Alliance common stock at an initial conversion price of $0.3725 [$7.0775 post-split] and the related 503,356 [26,492 post-split] warrants have an exercise price of $0.3725 [$7.0775 post-split]. The conversion price on the $750,000 convertible note was reduced to $0.215 [$4.085 post-split] per share in January 2019. The remaining $500,000 tranche of the notes was convertible into shares of Alliance common stock at a conversion price of $0.20 [$3.80 post-split] and the related 625,000 [32,895 post-split] warrants had an exercise price of $0.30 [$5.70 post-split]. All of these notes (an aggregate of $1.25 million in principal amount) converted automatically into Alliance common stock upon the closing of the Company’s acquisition on February 1, 2019 and were distributed to certain of the Company’s common shareholders.

Pursuant to the SPA, between June 29, 2018 and October 16, 2018, Alliance sold SCWorx Acquisition Corp. convertible notes in the aggregate principal amount of $750,000 and warrants to purchase 503,356 [26,492 post-split] shares of Alliance common stock, for an aggregate purchase price of $750,000. Each of the notes bore interest at 10% annually and had a one year term. The warrants had an exercise price of $0.3725, [$7.0775 post-split] a term of five years and were vested upon grant. As noted above, these notes automatically converted into Alliance common stock upon the closing of the Company’s acquisition on February 1, 2019.

On August 20, 2018, the Company and its stockholders entered into a Stock Exchange Agreement with Alliance, as amended December 18, 2018 (“SEA”). Under the SEA, the Company’s shareholders agreed to sell all of the issued and outstanding common stock of the Company, in exchange for which Alliance agreed to issue at the closing100,000,000shares of Alliance common stock to the Company’s stockholders.

Pursuant to the SPA, between November 16, 2018 and December 31, 2018, the Company purchased additional Alliance convertible notes in the aggregate principal amount of $275,000 and warrants to purchase 356,250 [18,750 post-split] shares of Alliance common stock, for an aggregate purchase price of $275,000. Each of the Notes bore interest at 10% annually and matured one year from the issue date. These warrants had an exercise price of $0.30 [$5.70 post-split], a term of five years and were vested upon grant. This brought the total amount funded by the Company to $1,035,000 as of December 31, 2018. In January 2019, SCWorx purchased $215,000 of additional Alliance convertible notes under the aggregate $1,250,000 SPA. These notes automatically converted into Alliance common stock upon the closing of the Company’s acquisition on February 1, 2019 and were purchased under the aggregate $1.25 million terms of the SPA.

In anticipation of the acquisition of the Company, Alliance filed an original listing application with the Nasdaq Capital Market to list the common stock of the combined company. On February 1, 2019, Nasdaq approved the listing of Alliance’s common stock (on a combined basis with the Company), with the result being that the newly combined company’s common stock is now newly listed on the Nasdaq Capital Market.

 

On February 1, 2019, SCWorx Corp. changed its name to SCW FL Corp. to allow Alliance to change its name to SCWorx Corp. AllianceMMA completed the acquisition of SCWorx, Corp. (n/k/a SCW FL Corp.), at which point Alliance changed its name to SCWorx Corp., changed its ticker symbol to “WORX”, and effected a one-for-nineteen reverse stock split of its common stock [bracketed amounts represent post-split adjusted shares or per share amounts], which combined the 100,000,000 Alliance shares of common stock issued to the Company’s shareholders into 5,263,158 shares of common stock of the newly combined company.

 

From a legal perspective, Alliance MMA acquired SCWSCWorx FL Corp.,Corp, and as a result, historical equity awards including stock options and warrants are carried forward at their historical basis.

 

From an accounting perspective, Alliance MMA was acquired by SCWSCWorx FL Corp.Corp in a reverse merger and as a result, the Company has completed preliminary purchase accounting for the transaction.

 

9

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Operations of the Business

 

SCWorx is a leading provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers and big data analytics for the healthcare industry.

 

SCWorx has developed and markets health information technology solutions and associated services that improve healthcare processes and information flow within hospitals. SCWorx’s software platform enables healthcare providers to simplify, repair, and organize its data (“data normalization”), allows the data to be utilized across multiple internal software applications (“interoperability”) and provides the basis for sophisticated data analytics (“big data”). SCWorx’s solutions are designed to quickly and accurately improve the flow of information quickly and accurately between the existing supply chain, electronic medical records, clinical systems, and patient billing functions. The software is designed to achieve multiple operational benefits such as supply chain cost reductions, decreased accounts receivables aging, accelerated and more accurate billing, contract optimization, increased supply chain management and cost visibility, synchronous Charge Description Master (“CDM”) and control of vendor rebates and contract administration fees.

 


SCWorx empowers healthcare providers to maintain comprehensive access and visibility to an advanced business intelligence that enables better decision-making and reductions in product costs and utilization, ultimately leading to accelerated and accurate patient billing. SCWorx’s software modules perform separate functions as follows:

 

Virtualized Item Master File repair, expansion and automation
virtualized Item Master File repair, expansion and automation;

 

CDM Management

CDM management;

 

Contract Management
contract management;

 

Request for Proposal Automation
request for proposal automation;

 

Rebate Management
rebate management;

 

Big Data Analytics Model
big data analytics modeling; and

 

Data Integration and Warehousing
data integration and warehousing.

 

SCWorx continues to provide transformational data-driven solutions to some of the finest, most well-respected healthcare providers in the United States. Clients are geographically dispersed throughout the country. The Company’s focus is to assist healthcare providers with issues they have pertaining to data interoperability. SCWorx provides these solutions through a combination of direct sales and relationships with strategic partners.

 

SCWorx’s software solutions are delivered to clients within a fixed term period, typically a three-to-five-year contracted term, where such software is hosted in SCWorx data centers (Amazon Web Service’s “AWS” or RackSpace) and accessed by the client through a secure connection in a software as a service (“SaaS”) delivery method.

 

SCWorx currently sells its solutions and services in the United States to hospitals and health systems through its direct sales force and its distribution and reseller partnerships.

 

SCWorx, as part of the acquisition of Alliance MMA, operates an online event ticketing platform focused on serving regional MMA (“mixed martial arts”) promotions.

 

The Company currently hosts its solutions, serves its customers, and supports its operations in the United States through an agreement with a third party hosting and infrastructure provider, RackSpace. The Company incorporates standard IT security measures, including but not limited to; firewalls, disaster recovery, backup, etc. The Company’s operations are dependent upon the integrity, security and consistent operation of various information technology systems and data centers that process transactions, communication systems and various other software applications used throughout its operations. Disruptions in these systems could have an adverse impact on the Company’s operations. The Company could encounter difficulties in developing new systems or maintaining and upgrading existing systems. Such difficulties could lead to significant expenses or to losses due to disruption in the Company’s business operations.

In addition, the Company’s information technology systems are subject to the risk of infiltration or data theft. The techniques used to obtain unauthorized access, disable or degrade service, or sabotage information technology systems change frequently and may be difficult to detect or prevent over long periods of time. Moreover, the hardware, software or applications the Company develops or procures from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of the Company’s information systems. Unauthorized parties may also attempt to gain access to the Company’s systems or facilities through fraud or deception aimed at its employees, contractors or temporary staff. In the event that the security of the Company’s information systems is compromised, confidential information could be misappropriated, and system disruptions could occur. Any such misappropriation or disruption could cause significant harm to the Company’s reputation, lead to a loss of sales or profits or cause the Company to incur significant costs to reimburse third parties for damages.


On March 16, 2020, in response to the COVID-19 pandemic, SCWorx established a wholly-owned subsidiary, Direct-Worx, LLC to endeavor to source and provide critical, difficult-to-find items for the healthcare industry. Items have become difficult to source due to unexpected disruptions within the supply chain, such as the COVID-19 pandemic. These products the Company has sought to source include: 

 10Test Kits — the Company has identified potential sources for Rapid Test Kits for COVID-19, but currently has no contracted supply of Rapid Test Kits.

 PPE — Personal Protective Equipment (PPE) includes items such as masks, gloves, gowns, shields, etc.

  

SCWorx Corp.

NotesThe sale of PPE and rapid test kits for COVID-19 represents a new business for the Company and is subject to Condensed Consolidated Financial Statements

(Unaudited)the myriad risks associated with any new venture. The Company has for example encountered great difficulty in attempting to secure reliable sources of supply for both COVID-19 Rapid Test Kits and PPE including, 3M N95 masks, which are the preferred medical grade mask of US healthcare companies. Further, the Company has encountered shipping delays with regard to masks and other PPE, and significant quality related issues regarding N95 masks. In addition, regarding the Company’s sourcing of COVID-19 Rapid Test Kits, the Company has encountered significant shipping delays, as well as reduced quantities. In addition, the Company currently has no contracted supply of Rapid Test Kits. Consequently, there is no assurance as to whether the Company will be able to source a reliable supply of COVID-19 test kits. For the three and six months ended June 30, 2020, the Company did not complete the sale of any COVID-19 rapid test kits, and completed minimal sales of PPE. As of June 30, 2020, the Company had approximately 47,000 test kits and approximately 40,000 sampling kits in inventory. In addition, changes in FDA processes governing the sale of COVID-19 serology tests could have the effect of rendering the COVID-19 serology tests to be sold by the Company not saleable in the United States, which could have a material adverse effect on the Company. There can be no assurance that the Company will be able to generate any significant revenue from the sale of PPE products or rapid test kits. As of the date of this report, the Company has not generated any material revenue from the sale of PPE or rapid test kits.

 

Impact of the COVID-19 Pandemic

The Company’s operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and the world. The New York and New Jersey area, where the Company is headquartered, was at one of the early epicenters of the coronavirus outbreak in the United States. The outbreak has since spread to the rest of the country and is impacting new customer acquisition. The Company has been following the recommendations of local health authorities to minimize exposure risk for its team members since the outbreak.

In addition, the Company’s customers (hospitals) have also experienced extraordinary disruptions to their businesses and supply chains, while experiencing unprecedented demand for health care services related to COVID-19. As a result of these extraordinary disruptions to the Company’s customers’ business, the Company’s customers are currently focused on meeting the nation’s health care needs in response to the COVID-19 pandemic. As a result, there is a significant risk that the Company’s customers will not be able to focus any resources on expanding the utilization of the Company’s services, which could adversely impact its future growth prospects, at least until the adverse effects of the pandemic subside. In addition, the financial impact of COVID-19 on the Company’s hospital customers could cause the hospitals to delay payments due to the Company for services, which could negatively impact the Company’s cash flows.

The Company is endeavoring to mitigate these risks to revenue through the sale of personal protective equipment (“PPE”) and COVID-19 rapid test kits to the health care industry, including many of the Company’s hospital customers. The Company’s Chief Executive Officer and employees have experience in the healthcare industry and industry contacts, and a database of items designed to assist the healthcare industry in fulfilling its inventory demands.

On March 16, 2020, in response to the COVID-19 pandemic, SCWorx established a wholly-owned subsidiary, Direct-Worx, LLC to endeavor to source and provide critical, difficult-to-find items for the healthcare industry. Items have become difficult to source due to unexpected disruptions within the supply chain, such as the COVID-19 pandemic.


Note 2. Liquidity and Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.

 

The Company’s primary need for liquidity is to fund the working capital needs of the business and general corporate purposes. The Company has historically incurred losses and has relied on borrowings from membersand equity capital to fund the operations and growth of the business. The Company has suffered recurring losses from operations and incurred a net loss of $4,899,453 for the six months ended June 30, 2020. As of June 30, 2019,2020, the Company had cash of approximately $1.3 million, negative$334,500, a working capital deficit of approximately $0.6 million$2,164,960, and an accumulated deficit of approximately $9.7 million.

During 2018,$17,693,926. The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its operating expenses will continue to increase and, as a result, the Company beganwill eventually need to gain traction with more hospitals and witnessed customer renewals of expiring agreements with existing customers. During the first quarter of 2019, the Company signed four contracts with new customers and during the second quarter completed a number of data consulting projects as proof of concept for potentially new customers. The Company’s target is to sign on average, a contract a month, with new customers during 2019. Management expectsgenerate significant increases in revenueproduct revenues to provide sufficient cash flowachieve profitability. These conditions indicate that there is substantial doubt about the Company’s ability to fundcontinue as a going concern within one year after the operations for at least the one-year period following the release of these condensed consolidated financial statements.statements issuance date.

 

On November 30, 2018,May 5, 2020, the Nasdaq Stock Market informed the Company completedthat it had initiated a common stock private“T12 trading halt,” which means the halt will remain in place of $1.25 million. In February 2019, the transactions related to the purchase of Alliance MMA resulted in a gross increase of cash of $5.4 million whichuntil the Company has utilized a significant portion to operate the business. Management believes the remaining cash balance of $1.3 million along with anticipated increases in salesfully satisfied Nasdaq’s request for additional information. This trading halt was lifted on August 10, 2020.

The Company is expectedevaluating various alternatives, including reducing operating expenses, securing additional financing through debt or equity securities to fund operations for at least the next 12 months; however,future business activities and other strategic alternatives. There can be no assurance that the Company will thereafter needbe able to raisegenerate the level of operating revenues in its business plan, or if additional funding through strategic relationships, public or private equity or debt financings. If such funding is not available or notsources of financing will be available on acceptable terms, acceptable to the Company,if at all. If no additional sources of financing are available, the Company’s current plans for expansion, including new product development,future operating prospects may be curtailed or cancelled.adversely affected. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

11

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 3. Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying unaudited condensed consolidated financial statements include the accounts of SCWorx and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. 

These interim unaudited condensed consolidated financial statements as of June 30, 2019 and 2018, and for the three and six months then ended, have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) for interim financial information. The amounts as of December 31, 2018 have been derived from the Company’s annual audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rulesfor interim financial information. They do not include all of the information and regulations. In the opinion of management, the accompanyingfootnotes required by U.S. GAAP for complete consolidated financial statements. Therefore, these unaudited condensed consolidated financial statements reflect all adjustments necessary (consisting of normal recurring adjustments) to state fairly the financial position of the Company and its results of operations and cash flows as of and for the periods presented. These financial statements should be read in conjunction with the annualCompany’s audited financial statements and notes thereto as of and for the year ended December 31, 2018, includedcontained in the Company’s Annual Reportits report on Form 10-K for the year ended December 31, 2018.2019 filed with the SEC on June 12, 2020.

 

The unaudited condensed consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at June 30, 2020, and the results of its operations and cash flows for the three and six months ended June 30, 2020. The results of operations for the three month and six months ended June 30, 20192020 are not necessarily indicative of the results that mayto be expected for future quarters or the full year ended December 31, 2019 or any future period and the Company makes no representations related thereto.year.


Reclassifications

 

Reclassification

A reclassification has been made to the Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of ChangesCertain balances in Stockholders’ Equity/(Deficit) to break out the Series A Convertible Preferred stock par value of $819 and additional paid in capital of $7,980,126. Previously, for the quarter ended March 31, 2019, the entire balance was disclosed as Preferred Stock. This change in classification does not affect the previously reported total stockholders’ equity balance. In addition, the authorized common stock has been restated to reflect the correct amount of 45,000,000 authorized common shares.

In addition, certain prior quarter amountsissued consolidated financial statements have been reclassified for consistencyto be consistent with the current quarterperiod presentation. These reclassificationsThe reclassification had no effectimpact on reported results of operationstotal financial position, net income, or cash flows.stockholders’ equity.

 

Cash

 

Cash is maintained with various financial institutions. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. There were no amounts in excess of the FDIC insured limit as of June 30, 2020 and December 31, 2019.

 

Fair Value of Financial Instruments

 

Management applies fair value accounting for significant financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Management defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, management considers the principal or most advantageous market in which wethe Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Inputs that are generally unobservable and typically reflect management'smanagement’s estimate of assumptions that market participants would use in pricing the asset or liability.

 

Concentration of Credit and Other Risks

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, accounts receivable due from shareholder and convertible notes receivable.warrants. The Company believes that any concentration of credit risk in its accounts receivable is substantially mitigated by the Company’s evaluation process, relatively short collection terms and the high level of credit worthiness of its customers. The Company performs ongoing internal credit evaluations of its customers’ financial condition, obtains deposits and limits the amount of credit extended when deemed necessary but generally requires no collateral. The Company believes that any concentration of credit risk in its due from shareholder and convertible notes receivable was substantially mitigated by

For the shareholder’s material interest inquarter ended June 30, 2020, the Company ability to sell off portionshad one customer representing 26% of the interest, if necessary, and the closing of the acquisition of SCWorx by Alliance and conversion of the notes payable - related party into Series A Convertible Preferred share and the settlement of the due from stockholder balance with the surrender of 1,401 SCWorx common shares in January 2019.

aggregate revenues. For the quarter ended June 30, 2019, the Company had 3three customers representing 23%, 19% and 11% of aggregate revenues. For the quarter endedAt June 30, 2018,2020, the Company had 3four customers representing 23%15%, 21%13%, 13% and 12%11% of aggregate revenues.accounts receivable. At June 30, 2019, the Company had 4four customers representing 18%, 16% and, 13%, and 12% of aggregate accounts receivable. At December 31, 2018, the Company had 3 customers representing 39%, 21% and 13% of aggregate accounts receivable. 

 

12

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Allowance for Doubtful Accounts

 

The Company continually monitors customer payments and maintains a reserve for estimated losses resulting from its customers'customers’ inability to make required payments. In determining the reserve, the Company evaluates the collectability of its accounts receivable based upon a variety of factors. In cases where the Company becomes aware of circumstances that may impair a specific customer'scustomer’s ability to meet its financial obligations, the Company records a specific allowance against amounts due. For all other customers, the Company recognizes allowances for doubtful accounts based on its historical write-off experience in conjunction with the length of time the receivables are past due, customer creditworthiness, geographic risk and the current business environment. Actual future losses from uncollectible accounts may differ from the Company'sCompany’s estimates. The Company deemed noCompany’s allowance for doubtful accounts necessary as of June 30, 20192020 and December 31, 2018.2019 was $311,266 and $344,412, respectively.

 

LeasesInventory

 

We determine if an arrangementThe inventory balance at June 30, 2020 is a lease at inception. Operating leasesrelated to the Company’s Direct-Worx, LLC subsidiary and consisted of approximately 47,000 testing kits and approximately 40,000 sampling kits. These items are included incarried on the lease right-of-use (“ROU”) assets, current portion and long-term portion of lease obligations on ourunaudited condensed consolidated balance sheet. ROU assets represent our rightsheet at cost. A company affiliated with a shareholder advanced the cash to use an underlying asset for the lease termsupplier of the test kits and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement dateamount due is recorded in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments to be made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease, which are included in the lease ROU asset when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease components only, none with non-lease components, which are generally accounted for separately.accounts payable.

 

9

Business Combinations

 

The Company includes the results of operations of a business it acquires in its consolidated results as of the date of acquisition. The Company allocates the fair value of the purchase consideration of its acquisition to the tangible assets, liabilities and intangible assets acquired, based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. The primary items that generate goodwill include the value of the synergies between the acquired businesses and the Company. Intangible assets are amortized over their estimated useful lives. The fair value of contingent consideration (earn out) associated with acquisitions is remeasured each reporting period and adjusted accordingly. Acquisition and integration related costs are recognized separately from the business combination and are expensed as incurred. For additional information regarding the Company’s acquisitions, refer to “Note 4 – Business Combinations.”

Goodwill and Purchased Identified Intangible Assets

Goodwill.

Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and identified intangible assets acquired under a business combination. Goodwill also includes acquired assembled workforce, which does not qualify as an identifiable intangible asset. The Company reviews impairment of goodwill annually in the third quarter, or more frequently if events or circumstances indicate that the goodwill might be impaired. The Company first assesses qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. If, after assessing the totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then the quantitative goodwill impairment test is unnecessary.

 

Identified intangible assets.

Identified finite-lived intangible assets consist of ticketing software and promoter relationships resulting from the February 1, 2019 business combination. The Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives, ranging from 5 to 7 years. The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life.

For further discussion of goodwill and identified intangible assets, see “Noterefer to Note 4, – Business Combinations.”Intangible Assets.

 

Property and Equipment

 

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the related assets’ estimated useful lives. Equipment, furniture and fixtures are being amortized over a period of three years.

 

Expenditures that materially increase asset life are capitalized, while ordinary maintenance and repairs are expensed as incurred.

 

Depreciation expense for the three months ended June 30, 2020 and 2019 was $17,257 and $1,353, respectively. Depreciation expense for the six months ended June 30, 2020 and 2019 was $19,516 and $1,804, respectively.

13

10

 

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Revenue Recognition

The Company recognizes revenue in accordance with Topic 606 to depict the transfer of promised goods or services in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of Topic 606 the Company performs the following steps:

 

·Step 1: Identify the contract(s) with a customer

·Step 2: Identify the performance obligations in the contract

·Step 3: Determine the transaction price

·Step 4: Allocate the transaction price to the performance obligations in the contract

·Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

 

The Company follows the accounting revenue guidance under Topic 606 to determine whether contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer.

 

The Company has identified the following performance obligations in its contracts with customers:

 

 1)Data Normalization: which includes data preparation, product and vendor mapping, product categorization, data enrichment and other data related services,

 

 2)Software-as-a-service (“SaaS”): which is generated from clients’ access of and usage of the Company’s hosted software solutions on a subscription basis for a specified contract term, which is usually annually. In SaaS arrangements, the client cannot take possession of the software during the term of the contract and generally has the right to access and use the software and receive any software upgrades published during the subscription period,

 

 3)Maintenance: which includes ongoing data cleansing and normalization, content enrichment, and optimization, and

 

 4)Professional Services: mainly related to specific customer projects to manage and/or analyze data and review for cost reduction opportunities.opportunities, and
5)PPE: which includes items such as masks, gloves, gowns, shields, etc.

  

A contract will typically include Data Normalization, SaaS and Maintenance, which are distinct performance obligations and are accounted for separately. The transaction price is allocated to each separate performance obligation on a relative stand-alone selling price basis. Significant judgement is required to determine the stand-alone selling price for each distinct performance obligation and is typically estimated based on observable transactions when these services are sold on a stand-alone basis. At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when the performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the good or service, and the customer is able to direct the use of, and obtain substantially all the remaining benefits from, the good or service. 

14

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

  

The Company’s SaaS and Maintenance contracts typically have termination for convenience without penalty clauses and accordingly, are generally accounted for as month-to-month agreements. If it is determined that the Company has not satisfied a performance obligation, revenue recognition will be deferred until the performance obligation is deemed to be satisfied.

 


Revenue recognition for the Company’s performance obligations are as follows:

 

Data Normalization and Professional Services

The Company’s Data Normalization and Professional Services are typically fixed fee. When these services are not combined with SaaS or Maintenance revenues as a single unit of accounting, these revenues are recognized as the services are rendered and when contractual milestones are achieved and accepted by the customer.

 

Software-as-a-ServiceSaaS and Maintenance

Software-as-a-service

SaaS and maintenanceMaintenance revenues are recognized ratably over the contract terms beginning on the commencement date of each contract, which is the date on which the Company’s service is made available to customers. 

  

The Company does have some contracts that have payment terms that differ from the timing of revenue recognition, which requires the Company to assess whether the transaction price for those contracts includeincludes a significant financing component. The Company has elected the practical expedient that permits an entity to not adjust for the effects of a significant financing component if it expects that at the contract inception, the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. The Company does not maintain contracts in which the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service exceeds the one-year threshold.

In periods prior to the adoption of ASC 606, the Company recognized revenues when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and the collectability of the resulting receivable is reasonably assured. The adoption of Topic 606 did not result in a cumulative effect adjustment to our opening retained earnings since there was no significant impact upon adoption of Topic 606. There was also no material impact to revenues, or any other financial statement line items for the year ended December 31, 2018 as a result of applying ASC 606.

 

The Company has one principal revenue stream, from the SaaS business, and believes it has not presented anyall varying factors that affect the nature, timing and uncertainty of revenues and cash flows.

 

There were noPPE sales

PPE revenues that wereare recognized fromonce the customer obtains physical possession of the product(s). Because the Company acts as an agent in arranging the relationship between the customer and the supplier, PPE revenues are presented net of related costs, including product procurement, warehouse and shipping fees, etc.

Remaining Performance Obligations

As of June 30, 2020 and December 31, 2019, the Company had $1,827,262 and $1,056,637, respectively, of remaining performance obligations that were partially satisfied priorrecorded as contract liabilities. The Company expects to January 1, 2018.recognize a majority of sales relating to these existing performance obligations of $1,827,262 during the remainder of 2020.

 

Costs to Obtain and Fulfill a Contract

 

Costs to fulfill a contract typically include costs related to satisfying performance obligations as well as general and administrative costs that are not explicitly chargeable to customer contracts. These expenses are recognized and expensed when incurred in accordance with ASC 340-40.

 

15

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Cost of RevenueRevenues

 

Cost of revenues primarily representsrepresent data center hosting costs, consulting services and maintenance of the Company’s large data array that were incurred in delivering professional services and maintenance of the Company’s large data array during the periods presented.

 

Contract Balances

 

Contract assets arise when the associated revenue associatedwas earned prior to the Company’s unconditional right to receive a payment under a contract with a customer (i.e., unbilled(unbilled revenue) and are derecognized when either it becomes a receivable or the cash is received. There were no contract assets as of June 30, 20192020 and December 31, 2018.2019.

12

 

Contract liabilities arise when customers remit contractual cash payments in advance of the Company satisfying its performance obligations under the contract and are derecognized when the revenue associated with the contract is recognized when the performance obligation is satisfied. Contract liabilities were approximately $912,000$1,827,262 and $817,000$1,056,637 as of June 30, 20192020 and December 31, 2018,2019, respectively.

Research and Development Costs

The Company expenses all research and development related costs as incurred. Research and development cost for the quarters ended June 30, 2019 and 2018 was approximately $478,000 and $0, respectively. Research and development cost for the six months ended June 30, 2019 and 2018 was approximately $660,000 and $0, respectively. These research and development cost relate to a new product development and programming expenses expected to be released during 2019.

Advertising Costs

The Company expenses advertising costs as incurred. There were no advertising costs for the quarters or six months ended June 30, 2019 and 2018.

Income Taxes

The Company converted to a corporation from a limited liability company during 2018.

 

The Company uses the asset and liability method of accounting for income taxes in accordance with Accounting Standard Codification (“ASC”) Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.

 

Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2020 and December 31, 2019, the Company has evaluated available evidence and concluded that the Company may not realize all the benefitbenefits of its deferred tax assets; therefore, a valuation allowance has been established for its deferred tax assets.

 

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

On December 22, 2017,March 27, 2020, the Tax CutsCoronavirus Aid, Relief, and JobsEconomic Security Act of 2017, (“the Tax(the “CARES Act”) was enacted.signed into law. The TaxCARES Act, significantly revised the U.S. corporate incomeamong other things, includes provisions relating to refundable payroll tax regime by, including but not limited to, lowering the U.S. corporate incomecredits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax rate from 34% to 21% effective January 1, 2018, implementing a territorial tax system, imposing a one-time transition tax on previously untaxed accumulated earnings and profits of foreign subsidiaries, and creating new taxes on foreign sourced earnings. As of June 30, 2019, we completed the accounting for tax effects of the Tax Act under ASC 740. There were no impactscredit refunds, modifications to the reporting period ended June 30, 2019.

16

SCWorx Corp.

Notesnet interest deduction limitations and technical corrections to Condensed Consolidated Financial Statements

(Unaudited)tax depreciation methods for qualified improvement property. The Company continues to examine the impact that the tax changes in the CARES Act may have on its business but does not expect the impact to be material.

 

The income tax expense for the quartersthree months ended June 30, 20192020 and 2018 was $195,000 and $0, respectively, and2019 was $0 and $0$195,000, respectively. The income tax expense for the six months ended June 30, 2020 and 2019 and 2018, respectively, and are included in prepaid assets and accounts payable and accrued liabilities on the condensed consolidated balance sheet.was $0.

 

Stock-basedStock-Based Compensation Expense

 

The Company accounts for stock-based compensation expense in accordance with the authoritative guidance on share-based payments. Under the provisions of the guidance, stock-based compensation expense is measured at the grant date based on the fair value of the option or warrant using a Black-Scholes option pricing model and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair value of the Company’s stock awards for non-employees is estimated based on the fair market value on each vesting date, accounted for under the variable-accounting method.

 

The authoritative guidance also requires that the Company measuremeasures and recognizerecognizes stock-based compensation expense upon modification of the term of stock award. The stock-based compensation expense for such modification is accounted for as a repurchase of the original award and the issuance of a new award.

 


Calculating stock-based compensation expense requires the input of highly subjective assumptions, including the expected term of the stock-based awards, stock price volatility, and the pre-vesting option forfeiture rate. The Company estimates the expected life of options granted based on historical exercise patterns, which are believed to be representative of future behavior. The Company estimates the volatility of the Company’s common stock on the date of grant based on historical volatility. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of managementmanagement’s judgment. As a result, if factors change and the Company uses different assumptions, its stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience of its stock-based awards that are granted, exercised and cancelled. If the actual forfeiture rate is materially different from the estimate, stock-based compensation expense could be significantly different from what was recorded in the current period. The Company also grants performance based restricted stock awards to employees and consultants. These awards will vest if certain employee\consultant-specific or company-designated performance targets are achieved. If minimum performance thresholds are achieved, each award will convert into a designated number of the Company’s common stock. If minimum performance thresholds are not achieved, then no shares will be issued. Based upon the expected levels of achievement, stock-based compensation is recognized on a straight-line basis over the requisite service period. The expected levels of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change, stock-based compensation is adjusted in the period of change and recorded on the statements of operations and the remaining unrecognized stock-based compensation is recorded over the remaining requisite service period. See “Note 10 –Refer to Note 8, Stockholders’ Equity”Equity, for additional detail.

Loss Per Share

The Company computes earnings (loss) per share in accordance with ASC 260, “Earnings per Share” which requires presentation of both basic and diluted earnings (loss) per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing the loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of June 30, 2020 and 2019, the Company had 1,060,576 and 1,450,563, respectively, of common stock equivalents outstanding.

Indemnification

 

The Company provides indemnification of varying scope to certain customers against claims of intellectual property infringement made by third parties arising from the use of the Company’s software. In accordance with authoritative guidance for accounting for guarantees, the Company evaluates estimated losses for such indemnification. The Company considers such factors as the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of loss. To date, no such claims have been filed against the Company and no liability has been recorded in the Company’sits condensed consolidated financial statements.

 

As permitted under Delaware law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company believes, given the absence of any such payments in the Company’s history, and the estimated low probability of such payments in the future, that the estimated fair value of these indemnification agreements is immaterial.unlimited. In addition, the Company has directors’ and officers’ liability insurance coverage that is intended to reduce its financial exposure and may enable the Companyit to recover any payments above the applicable policy retention, should they occur.

In connection with the Class Action and derivative claims and investigations described in Note 7, Commitments and Contingencies, the Company obligated to indemnify its officers and directors for costs incurred in defending against these claims and investigations. Because the Company currently does not have the resources to pay for these costs, its directors and officers liability insurance carrier has agreed to indemnify these persons even though the $750,000 retention under such policy has not yet been met. Ultimately, the Company will be obligated to pay the amount of the retention to the extent of actual settlement and defense costs, which payments could have a material adverse effect on the Company.

 

From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. Contingencies

The Company records a liability in its consolidated financial statements for these matters when the Company believes that it is both probable that a loss is known or considered probablehas been incurred and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. IfCompany determines that a loss is probable butreasonably possible, and the amountloss or range of loss cannotcan be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made).in the notes to the consolidated financial statements. The Company does not recognize gainreviews the developments in its contingencies until they are realized. that could affect the amount of the provisions that has been previously recorded, and the matters and related possible losses disclosed. The Company adjusts provisions and changes to its disclosures accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. Significant judgment is required to determine both the probability and the estimated amount.

Legal costs incurred in connectionassociated with loss contingencies are expensed as incurred. See “Note 9 – Commitments and Contingencies,” for further information.accrued based upon legal expenses incurred by the end of the reporting period.

 

17


SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. The accountingCompany regularly evaluates estimates and assumptions that require management’s most significant, difficult, and subjective judgment includerelated to the accountingallowance for doubtful accounts, the business combination, the recognition of revenue, collectability of accounts receivable, valuation of convertible notes receivable and related warrants, the assessment of recoverability of goodwill and intangible assets, the assessment ofestimated useful lives and the recoverability of property and equipment, the valuation and recognition oflong-lived assets, stock-based compensation, expense, loss contingencies,goodwill, and deferred income taxes.tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Actual results could differ materially from those estimates.

 

18

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update No. 2016-02,Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is provided for lessees of capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11,Leases (Topic 842) Targeted Improvements (“ASU 2018-11”). ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. ASU 2018-11 also allows lessors to not separate non-lease components from the associated lease component if certain conditions are met. The Company adopted the provisions of ASU 2016-02 and ASU 2018-11 in the quarter beginning January 1, 2019. The adoption resulted in the recognition of additional disclosures and a right of use asset of approximately $53,000 included as a component of prepaid expenses and other assets and a lease liability of approximately $53,000, which is included as a component of accounts payable and accrued liabilities.

 

In October 2018, the FASB issued ASU No. 2018-17, Consolidation(Topic (Topic 810):Targeted Improvements to Related Party Guidance for Variable Interest Entities (“(“ASU 2018-17”). ASU 2018-17 provides that indirect interests held through related parties in common control arrangements should be considered on a proportional basis for determining whether fees paid to decision makers and service providers are variable interests. ASU 2018-17 is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We do not expect the standard to have a material impact on our condensed consolidated financial statements.

In February 2018, the FASB issued new guidance (“ASU 2018-02”) to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts & Jobs Act. We have adopted thethis new standard effectiveon January 1, 2019,2020, and the adoption of the standard did not have a material impact on our condensed consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820):Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective in the first quarter of fiscal 2020, and earlier adoption is permitted. We do not expectadopted this new standard on January 1, 2020, and the adoption of the standard todid not have a material impact on our consolidated financial statements.

 

In January 2017, the FASB issued Accounting Standards UpdateASU No. 2017-04,Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which eliminates step two from the goodwill impairment test. Under ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value up to the amount of goodwill allocated to that reporting unit. This guidance will be effective for us inWe adopted this new standard on January 1, 2020, and the first quarteradoption of 2020 on a prospective basis, and early adoption is permitted. We do not expect the standard todid not have a material impact on our consolidated financial statements.

 

In June 2018,2016, the FASB issued ASU No. 2018-07, “Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting,2016-13, “Financial Instruments - Credit Losses (Topic 326),” which amendswas subsequently amended in February 2020 by ASU 2020-02 “Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842).” Topic 326 introduces an impairment model that is based on expected credit losses, rather than incurred losses, to estimate credit losses on certain types of financial instruments (e.g. accounts receivable, loans and held-to-maturity securities), including certain off-balance sheet financial instruments (e.g., loan commitments). The expected credit losses should consider historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments, over the existing accounting standardscontractual term. Financial instruments with similar risk characteristics may be grouped together when estimating expected credit losses. Topic 326 is effective for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. The effective date for the standard is for interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted, but no earlier than2022, including interim periods within those fiscal years. The Company is currently evaluating the Company’s adoption date of Topic 606. Theimpact the new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial application. The Company has adopted this new standard in the first quarter of fiscal 2019 and the adoption of the standard did notwill have a material impact on its consolidated financial statements.

 

19

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)Note 4. Intangible Assets

 

Note 4. Business Combinations

Preliminary purchase accounting

On February 1,Intangible assets as of June 30, 2020 and December 31, 2019 the Company’s shareholders exchanged all of its outstanding shares in exchange for 5,263,158 shares of Alliance common stock. Due to the Company’s shareholders acquiring a controlling interest in Alliance after acquisition, the transaction was treated as a reverse merger for accounting purposes, with SCWorx being the reporting company. In accordance with purchase accounting rules under ASC 805, the purchase consideration was $11,865,306.

The acquisition was accounted for under the acquisition method of accounting. The assets acquired, liabilities assumed and preliminary purchase allocation, which is based on estimates and valuations of management, is as follows:

  Estimated Useful
Life (years)
   Estimated
Fair Value
 
       
Cash     $5,441,437 
Goodwill      8,466,282 
Identifiable intangible assets:        
Ticketing software  5   64,000 
Promoter relationships  7   176,000 
Total identifiable intangible assets      240,000 
Accounts payable      (1,901,624)
Current liabilities - discontinued operations      (380,789)
Aggregate purchase price     $11,865,306 

The allocation of consideration to the assets acquired and liabilities assumed at their estimated acquisition date fair values are considered preliminary and may change within the permissible measurement period, not to exceed one year.

20

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Identified intangible assets consistconsisted of the following:

 

   June 30, 2019    June 30, 2020  December 31, 2019 
Intangible assets Useful Life Gross
Assets
  Accumulated
Amortization
  Net  Useful life Gross
assets
  Accumulated amortization  Net  Gross
assets
  Accumulated amortization  Net 
Ticketing software 5 years $64,000  $(5,334 $58,666  5 years $64,000  $(18,133) $45,867  $64,000  $(11,733) $52,267 
Promoter relationships 7 years   176,000   (10,476)  165,524  7 years  176,000   (35,619)  140,381   176,000   (23,048)  152,952 
Total intangible assets, gross   $240,000  $(15,810) $224,190 
Total intangible assets $240,000  $(53,752) $186,248  $240,000  $(34,781) $205,219 

 


Amortization expense for the quarterthree months ended June 30, 2020 and 2019, was $9,485 and 2018, was $9,486, and $0, respectively.

Amortization expense for the six months ended June 30, 2020 and 2019, was $18,971 and 2018, was $15,810, and $0, respectively.

 

As of June 30, 2019,2020, the estimated future amortization expense of amortizable intangible assets is as follows:

 

2019 (remaining 6 months) $18,971 
2020  37,943 
2021  37,943 
2022  37,943 
2023  37,943 
Thereafter  53,447 
  $224,190 

Goodwill

The changes to the carrying value of goodwill from January 1, 2019 through June 30, 2019 are reflected below:

December 31, 2018    
Goodwill related to the acquisition of Alliance MMA $8,466,282 
June 30, 2019 $8,466,282 
Year ending December 31,   
2020 (remaining 6 months of 2020) $18,972 
2021  37,943 
2022  37,943 
2023  37,943 
2024  26,209 
Thereafter  27,238 
Total $186,248 

 

Note 5. Related Party TransactionsLoan Payable

 

Receipt of CARES funding

On May 5, 2020, the Company obtained a $293,972 unsecured loan payable through the Paycheck Protection Program (“PPP”), which was enacted as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES ACT”). The funds were received from Bank of America through a loan agreement pursuant to the CARES Act. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act and used for payroll costs, rent, mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. While the full loan amount may be forgiven, the amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels or less than 60% of the loan proceeds are used for payroll costs. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan. The Company expects the loan to be fully forgiven. 

Note 6. Leases

Due from ShareholderOperating Leases

 

The Company’s founder and majority stockholder had provided cash advances on an unsecured and non-interest-bearing basis, during the first few years of operation. Beginning in 2016, the founder began receiving distributions from the Company. The amounts owed to, and due from, the shareholder have been netted in the accompanying consolidated balance sheets. In January 2019, this shareholder surrendered 1,401 common shares to the Company as settlement of the balance due. As of June 30, 2019, and December 31, 2018, the net balance due from the founder was approximately $0 and $1.4 million, respectively. The balance did not carry a maturity date and there were no repayment terms.

Due to Shareholder

In October 2016, the Company entered into an unsecured loan agreement with a minority shareholder for up to $1 million of borrowings for operating expenses. In November 2016 and January 2018, the Company entered into additional note agreements to provide up to an additional $2 million of aggregate borrowings for which the Company has guaranteed payment from its subsidiary. The interest rate for the notes is 10% per annum and the notes mature in January 2021. One of the notes bore interest at 10% for the first 90 days and was then adjusted to 18% per annum.

As previously mentioned, on August 20, 2018, the Company entered into a Stock Exchange Agreement with Alliance MMA, as amended December 18, 2018, in connection therewith this minority shareholder agreed to accept Series A Convertible Preferred Stock units having a face value equal to the total amount owed to him of $2.1 million in full satisfaction of such indebtedness (including principal and accrued interest).

As of June 30, 2019, and December 31, 2018, the notes payable - related party totaled $192,446 and $1,591,491 respectively.

The Company incurred interest expense of approximately $0 and $48,434 for the quarter ended June 30, 2019 and 2018, respectively, and $23,720 and $90,057, for the six months ended June 30, 2019 and 2018, respectively. The Company incurred no interest expense on the notes payable - related party since February 1, 2019 as the holder agreed to settle the principal and interest balance with Series A Convertible Preferred Stock.

As of June 30, 2019 and 2018, the accrued interest balance was $0 and $282,000, respectively. 

In addition, this shareholder also provided office space to the Company at no cost through January 2019.

21

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 6. Convertible Notes Receivable

On June 28, 2018, SCWorx Acquisition Corp. entered into a SPA with Alliance MMA, under which SCW LLC agreed to buy up to $1.0 million in principal amount of convertible notes and warrants to purchase up to 671,142 [35,323] shares of common stock. The notes were originally convertible into shares of common stock at a conversion price of $0.3725 [$7.0775] and bore interest at 10% annually. The warrants were originally exercisable for shares of common stock at an exercise price of $0.3725 [$7.0775].

Under the SPA, SCWorx Acquisition Corp. agreed to fund (i) $500,000 at the initial closing, (ii) a second tranche of $250,000 upon the signing of a business combination agreement with the Company and (iii) a third tranche of $250,000 upon mutual agreement of Alliance MMA and SCWorx.

On December 18, 2018, SCWorx agreed to increase the total amount of principal from $1.0 million to $1.25 million and to reduce the conversion price of the final $500,000 installment of the aggregate $1,250,000 note purchase to $0.20 [$3.80] per share. The warrant exercise price for the related warrants to purchase 625,000 [32,895,] shares was reduced to $0.30 [$5.70] per share.

Pursuant to the SPA, during 2018, SCWorx purchased convertible notes from Alliance MMA in the principal amount of $1,035,000 and warrants to purchase an aggregate of 859,606 [45,242] shares of common stock, for an aggregate purchase price of $1,035,000. The note for $750,000 bears interest at 10% annually and matures on July 31, 2019. This note was amended in January 2019 to reduce the conversion price to $0.215 [$4.09] per share. The related warrant to acquire 503,356 [26,492] common shares has an exercise price of $0.3725 [$7.0775], a term of five years and was vested upon grant. The note for $275,000 has a conversion price of $0.20 [$3.80], bore interest at 10% annually and matured on June 22, 2019. The warrant to acquire 356,250 [18,750] common shares has an exercise price of $0.30 [$5.70], a term of five years and was vested upon grant.

During the first quarter of 2019, SCWorx purchased additional convertible notes from Alliance MMA in the principal amount of $215,000 and warrants to purchase an aggregate of 268,750 [14,145] shares of common stock, for an aggregate purchase price of $215,000. The note for $215,000 had a conversion price of $0.20 [$3.80], bore interest at 10% annually and matured on June 22, 2019. The warrant to acquire 268,750 [14,145] common shares had an exercise price of $0.30 [$5.70], a term of five years and was vested upon grant.

The Alliance acquisition closed on February 1, 2019 and the principal, commitment costs and accrued interest related to the purchased Alliance convertible notes automatically converted into 6,883,319 [362,280] shares of Alliance common stock. In January 2019, the SCWorx board of directors declared a dividend of the 6,883,319 [362,280] when-converted shares of Alliance common stock, and related warrants, to the SCWorx shareholders, two of whom waived their rights to the dividend, resulting in the shares being distributed to shareholders who participated in the November 2018 stock offering by SCWorx Corp. (f/k/a SCWorx Acquisition Corp.) of $1.25 million.

As of December 31, 2018, the Company held a convertible note receivable from Alliance MMA with a balance of $837,317. The Company also received warrants from the transaction which were valued at $67,000.

22

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 7. Fair value of financial instruments

FASB ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a framework for measuring the fair value of assets and liabilities according to a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that are derived from assumptions based on management’s estimate of assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.

The hierarchy is broken down into the following three levels, based on the reliability of inputs:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs for assets or liabilities that are derived from assumptions based on management’s estimate of assumptions that market participants would use in pricing the assets or liabilities.

Fair value was determined on a recurring basis based on appraisals by qualified licensed appraisers and was adjusted for management’s estimates of costs to sell and holding period discounts.

The following table presents information as of December 31, 2018 about significant unobservable inputs (Level 3) used in the valuation of assets measured at fair value on a recurring basis:

Financial Instrument Fair Value  Valuation technique Significant Unobservable inputs
Convertible notes receivable $837,817  Monte Carlo Simulation Probability of conversion and interest rates on comparable financial instruments
Investment in warrants $67,000  Black-Scholes Option Pricing Model Common stock volatility and discount

The fair value of the convertible notes receivable (and related discount) at the date of issuance was determined using the Monte Carlo simulation, probability of conversion and comparable interest rates. In conjunction with the acquisition, the Company did not have any of these financial instruments at June 30, 2019.

The assumptions used to measure the fair value of the convertible notes receivable as of original issuance date and as of December 31, 2018 were as follows:

  Issuance
Dates
  December 31,
2018
 
Risk-Free Interest Rate  2.41%-2.47%  2.41%
Probability of conversion into equity  50%-90%  90%
Expected Volatility  91.95%  91.95%
Term   .09-.59 years   .09year 

The Company held warrants to purchase common shares of Alliance MMA.  The fair value of the warrant asset (and related discount) at the date of issuance was determined using the Black-Scholes option pricing model. The Black-Scholes model uses a combination of observable inputs (Level 2) and unobservable inputs (Level 3) in calculating fair value.

The assumptions used to measure the fair value of the warrants as of original issuance date and as of December 31, 2018 were as follows:

  Issuance
Date
  December 31,
2018
 
Risk-Free Interest Rate  2.47%  2.41%
Expected Dividend Yield  0%  0%
Expected Volatility  91.95%  91.95%
Term   5 years   5 years 
Fair Market Value of Common Stock $0.3275  $0.16 

The balances and levels of the assets measured at fair value on a recurring basis at December 31, 2018 are presented in the following table:

  Quoted       
  prices      
  in active  Significant    
  markets for  other  Significant 
  identical  observable  unobservable 
  assets  inputs  inputs 
  (level 1)  (level 2)  (level 3) 
          
Financial assets:            
             
Convertible notes receivable $     -  $     -  $837,317 
             
Investment in warrants -  -  67,000 
             
Total $-  $-  $904,317 

In relationto the acquisition, the Company no longer held these investments at June 30, 2019, thus there is no impact to the Condensed Consolidated Statement of Operations for the three months ended June 30, 2019 and as a result the three month results are not included in the table below.

A summary of the changes in the Company’s convertible notes receivable at fair value using significant unobservable inputs (Level 3) as of and for the six months ended June 30, 2019 is as follows:

   2019 
Convertible notes receivable, December 31, 2018 $837,317 
Notes issued (face value $215,000), at fair value  196,000 
Increase in fair value  531,405 
Conversion of notes into common stock  (1,564,722)
Investment in notes receivable, June 30, 2019 $ - 

A summary of the changes in the Company’s investment in warrants measured at fair value using significant unobservable inputs (Level 3) as of and for the six months ended June 30, 2019 is as follows:

2019
Investment in warrants, December 31, 2018$67,000
Warrants issued to the Company19,000
Increase in fair value55,000
Conversion of warrants into common stock(141,000)
Investment in warrants, June 30, 2019$-

The values of the investment in warrants at issuance and as of June 30, 2019 were $152,000 and $0, respectively, with a gain from the change in fair value of $55,000 for the six months ended June 30, 2019 and is component of other income in the accompanying condensed consolidated statement of operations.

23

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 8. Leases

Operating Leases

Under Topic 842, a contract is a lease, or contains a lease, if the contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. To determine whether a contract conveys the right to control the use of an identified asset for a period of time, an entity shall assess whether, throughout the period of use, the entity has both of the following: (a) the right to obtain substantially all of the economic benefits from use of the identified asset; and (b) the right to direct the use of the identified asset.

The Company leases office facilities under operating leases. Our principle executive office in New York City is under a month to month arrangement. The Company’s officeCompany also had a lease in Greenwich, CT which was set to expire in March 2020 and is now month-to-month.

The Company has a remaining lease of less than one year.operating leases for corporate, business and technician offices. Leases with aprobableterm of 12 months or less, including month-to-month agreements, are not recorded on the condensed consolidated balance sheet;sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense for these leases on a straight-line basisbases over the lease term. The Company’s only two remaining leases are month-to-month. As a practical expedient, the Company elected, for all office and facility leases, not to separate nonleasenon-lease components (e.g., common-area(common-area maintenance costs) from lease components (e.g., fixed(fixed payments including rent) and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company uses its incremental borrowing rate for purposes of discounting lease payments.

 

Lease expenseThe Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the quarters ended June 30, 2019date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 840. The Company elected the optional transition method and 2018 was approximately $11,000 and $26,000, respectively.

Lease expense foradopted the six months ended June 30, 2019 and 2018 was approximately $16,000 and $31,000, respectively.

Onnew guidance on January 1, 2019 on a modified retrospective basis with no restatement of prior period amounts. As allowed under the new accounting standard, the Company adopted Topic 842 usingelected to apply practical expedients to carry forward the modified retrospective approach.original lease determinations, lease classifications and accounting of initial direct costs for all asset classes at the time of adoption. The Company recorded operatingalso elected not to separate lease components from non-lease components and to exclude short-term leases from its condensed consolidated balance sheet. The Company’s adoption of the new standard as of January 1, 2019 resulted in the recognition of right-of-use assets (right-of-use assets) of approximately $53,000 and operating lease liabilities of approximately $53,000. There was no impact to the accumulated deficit upon adoption of Topic 842.

 

We have operating leases for corporate, business and technician offices.  Leases with a probable term of 12 months or less, including month-to-month agreements, are not recorded on the consolidated balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). Our leases have remaining lease terms of one to 15 months, none of which include options to extend the leases without a new arrangement.


As of June 30, 2019,2020, assets recorded under operating leases were approximately $32,000, which is included as a component of prepaid expenses and other assets.$0. Operating lease right of use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payment is ourthe Company’s incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

 

The following table presents supplemental consolidated balance sheet information related to our operating leases:

  As of
June 30, 2019
 
Right-of-use Assets $32,000 
Short-term operating lease liabilities $32,000 

For the three and six months ended June 30, 2020 and 2019, the components of lease expense were as follows:

 

  Three Months Ended
June 30, 2019
  Six Months Ended
June 30, 2019
 
Operating lease cost $5,000  $11,000 
         
Total lease cost $5,000  $11,000 

24

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

  For the three months ended  For the six months ended 
  June 30,  June 30, 
  2020  2019  2020  2019 
Operating lease cost $14,898  $5,000  $24,323  $11,000 
                 
Total lease cost $14,898  $5,000  $24,323  $11,000 

 

Other information related to leases was as follows:

 

  Three Months Ended
June 30, 2019
 
Supplemental Cash Flows Information    
     
Cash paid for amounts included in the measurement of operating lease liabilities:    
Operating cash flows for operating leases $11,250 
     
Weighted Average Remaining Lease term (months) – operating leases  9 
     
Weighted Average Discount Rate – operating leases  10%
  For the three months ended  For the six months ended 
  June 30,  June 30, 
  2020  2019  2020  2019 
Cash paid for amounts included in the measurement of operating lease liabilities:                
Operating cash flows for operating leases $14,898  $11,250  $24,323  $22,500 
                 
Weighted average remaining lease term (months) – operating leases  -   9   -   9 
                 
Weighted average discount rate– operating leases  N/A   10%  N/A   10%

The maturity analysis of the Company’s annual undiscounted cash flows of operating lease liabilities as of June 30, 2019 are as follows:

  Operating Lease 
Year Ending December 31, :   
2019 (excluding the quarters ended June 30, 2019) $22,500 
2020  11,250 
Total minimum lease payments 33,750 
Lease amount representing interest  (1,400)
Total lease liabilities $32,350 

There were no commitments for non-cancelable operating leases as of December 31, 2018 or June 30, 2019.

As of June 30, 2019, wehave2020, the Company has no additional operating leases, other than that noted above, and no financing leases.

Note 7. Commitments and Contingencies

In conducting its business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.

On April 29, 2020, a securities class action case was filed in the United States District Court for the Southern District of New York against the Company and its CEO. The action is captioned Daniel Yannes, individually and on behalf of all others similarly situated, Plaintiff vs. SCWorx Corp. and Marc S. Schessel, Defendants.


On May 27, 2020, a second securities class was filed in the United States District Court for the Southern District of New York against the Company and its CEO. The action is captioned Caitlin Leeburn, individually and on behalf of all others similarly situated, Plaintiff v. SCWorx Corp. and Marc S. Schessel, Defendants.

On June 23, 2020, a third securities class was filed in the United States District Court for the Southern District of New York against us and our CEO. The action is captioned Jonathan Charles Leonard, individually and on behalf of all others similarly situated, Plaintiff v. SCWorx Corp. and Marc S. Schessel, Defendants.

All three lawsuits allege that our company and our CEO mislead investors in connection with our April 13, 2020 press release with respect to the sale of COVID-19 rapid test kits. The plaintiffs in these actions are seeking unspecified monetary damages. We intend to vigorously defend against these proceedings.

On June 15, 2020, a shareholder derivative claim was filed in the United States District Court for the Southern District of New York against Marc S. Schessel, Charles K. Miller, Steven Wallitt (all of whom are current directors), and Robert Christie (a former director) (“Director Defendants”). The action is captioned Javier Lozano, derivatively on behalf of SCWorx Corp., Plaintiff, v. Marc S. Schessel, Charles K. Miller, Steven Wallitt, Defendants, and SCWorx Corp., Nominal Defendant. This lawsuit alleges that the Director Defendants breached their fiduciary duties to us, including by misleading investors in connection with our April 13, 2020 press release with respect to the sale of COVID-19 rapid test kits, failing to correct false and misleading statements and failing to implement proper disclosure and internal controls. The Plaintiff, on our behalf, is seeking an award of monetary damages to us, improvements in our disclosure and internal controls, and legal fees. The Director Defendants intend to vigorously defend against these proceedings.

In connection with these actions, the Company may be obligated to indemnify its CEO and its officers or directors who incur any liability or expense as a result of serving at the Company’s request in such capacity.

In addition, following the April 13, 2020 press release and related disclosures (related to COVID-19 rapid test kits), the Securities and Exchange Commission made an inquiry regarding the disclosures the Company made in relation to the transaction involving COVID-19 test kits. On April 22, 2020, the Securities and Exchange Commission ordered that trading in the securities of the Company be suspended because of “questions and concerns regarding the adequacy and accuracy of publicly available information in the marketplace” (the “SEC Trading Halt”). The SEC Trading Halt expired May 5, 2020, at 11:59 PM EDT. The Company is fully cooperating with the SEC’s investigation and is providing documents and other requested information.

In April 2020, the Company received related inquiries from The Nasdaq Stock Market and the Financial Industry Regulatory Authority (FINRA). The Company has been fully cooperating with these agencies and providing information and documents, as requested. On May 5, 2020, the Nasdaq Stock Market informed the Company that it had initiated a “T12 trading halt,” which means the halt will remain in place until the Company has fully satisfied Nasdaq’s request for additional information. The Company continues to fully cooperate with Nasdaq and respond to Nasdaq’s information requests as they are issued. The T12 trading halt was lifted on August 10, 2020.

Also in April 2020, the Company was contacted by the U.S. Attorney’s Office for the District of New Jersey, which is seeking information and documents from the Company’s officers and directors relating primarily to the April 13, 2020 press release concerning COVID-19 rapid test kits. The Company is fully cooperating with the U.S. Attorney’s Office in its investigation.

 

Note 9. Commitments and Contingencies

8. Stockholders’ Equity

 

Legal ProceedingsCommon Stock

Authorized Shares

 

InThe Company has 45,000,000 common shares authorized with a par value of $0.001 per share.


Issuance of Shares Pursuant to Conversion of Series A Preferred Stock

During January 2020, the normal courseCompany issued 5,264 shares of business or otherwise, we may become involved in legal proceedings. We will accruecommon stock to a liability forholder of its Series A Convertible Preferred Stock upon the conversion of 2,000 of such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a rangeshares of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.Series A Convertible Preferred Stock.

 

During February 2020, the Company issued an aggregate of 172,369 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 65,500 of such shares of Series A Convertible Preferred Stock.

25

 

SCWorx Corp.During April 2020, the Company issued an aggregate of 1,043,935 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 396,695 of such shares of Series A Convertible Preferred Stock.

Notes

During May 2020, the Company issued an aggregate of 51,316 shares of common stock to Condensed Consolidated Financial Statementsholders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 19,500 of such shares of Series A Convertible Preferred Stock.

(Unaudited)Issuance of Shares to Current and Former Employees and Directors

On January 8, 2020, the Company issued 50,000 shares of common stock to a former employee per the terms of a settlement agreement. 

 

On March 29, 2019, Network 1 Financial Securities Inc. (“Network One”) served12, 2020, the Company issued 16,667 shares of common stock to an employee pursuant to a complaint against Alliance.   Network One alleges that Alliance breached its obligation under its agreements with Alliance to indemnify  Network One for certain costs that Network One incurred in connection with the defense and settlement of the class action litigation previously instituted against Alliance and Network One.  This class action litigation has since been resolved, as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission on April 1, 2019. Network One has demanded approximately $135,000 in payment of alleged damages.  The Company does not believe that it owes the amount demanded and intends to vigorously defend against these claims.vesting schedule.

 

On December 19, 2018, the Company’s former CEO, Robert L. Mazzeo, who resigned on May 25, 2018, served a complaint against Alliance in the United States District Court for the Southern District of NY. Mr. Mazzeo alleges that he (i) was fraudulently induced to become the CEO ofApril 15, 2020, the Company and (ii) entered intoissued 3,913 shares of common stock to an employment contract withemployee pursuant to a vesting schedule.

On April 16, 2020, the Company and thatissued 5,264 shares of common stock to a director pursuant to a vesting schedule.

On April 21, 2020, the Company breached such contract. Mr. Mazzeo seeks damages in excessissued 30,303 shares of $500,000. The Company believes that the lawsuit is frivolous and violative of Rule 11 of the Federal Rules of Civil Procedure. The Company filed an answercommon stock to the complaint on February 5, 2019, and in addition to mounting a vigorous defense, filed counter claims against Mr. Mazzeo alleging breach of fiduciary duty. The Company does not believe that it owes the amount demanded and intends to vigorously defend against these claims.

In August 2018, SCWorx settled a dispute with a former employee for $260,000, of which approximately $132,000 was paid in 2018 and the balance of $128,000 was accrued at December 31, 2018. The remaining balance was paid in January 2019. The employee had sued the Company in Massachusetts Superior Court for compensation under an employment agreement.pursuant to a vesting schedule. 

 

Disputed Contract Claim

As part of Alliance’s public offering of shares of its common stock and warrants in January 2018, Alliance issued warrants with a provision requiring Alliance to pay the warrant holder the Black-Scholes value of the warrant upon a fundamental transaction as defined in the SPA. On August 20, 2018, Alliance entered into a Stock Exchange Agreement with SCWorx which upon the closing in February 2019, qualified as a fundamental transaction. The holders of the warrants had thirty days to notify SCWorx of the exercise of their rights under this provision, and two holders did so in the allotted time. The Company negotiated settlements with the warrant holders aggregating approximately $175,000 in fair value. During the second quarter 2019,June 24, 2020, the Company issued 19,80125,000 shares of common stock to an employee pursuant to a vesting schedule.

Issuance of Shares Pursuant to Exercises of Common Stock Warrants

On April 14, 2020, a holder of common stock warrants exercised 7,000 warrants for a cash payment of $38,570.

Issuance of Shares Pursuant to Cashless Exercises of Common Stock Warrants

During April 2020, holders of common stock warrants exercised an aggregate of 520,925 warrants using a cashless exercise into 321,155 shares of common stock.

During May 2020, holders of common stock warrants exercised an aggregate of 56,982 warrants using a cashless exercise into 26,034 shares of common stock.

Issuance of Shares Pursuant to Cashless Exercises of Stock Options

During April 2020, holders of common stock options exercised an aggregate of 105,028 options using a cashless exercise into 57,534 shares of common stock.


Issuance of Shares Pursuant to Settlement of Accounts Payable

On April 16, 2020, the Company issued 100,000 shares of common stock in full settlement of $640,517 of accounts payable. The shares had a fair value of $6.95 per shares.

On May 12, 2020, the Company issued 104,567 shares of common stock in full settlement of $93,150 of accounts payable. The shares had a fair value of $5.76 per shares.

On June 24, 2020, the Company issued 80,000 shares of common stock and approximately $55,000warrants to purchase 100,000 shares of common stock, of which 50,000 shall be exercisable at $3.80 per share and the remaining 50,000 shall be exercisable at $5.80 per share, in casheach case for a term of 5 years, in connection with the termination of a consulting arrangement and in full settlement of the claims.

Preferred Stock Penalty

On December 18, 2018, Alliance closed the placement of the first round of Series A Convertible Preferred securities purchase agreements pursuant to which such Series A Convertible Preferred Stock was issued. The terms of the convertible preferred stock agreements required SCWorx to register the underlying common shares under a Form S-1 within a prescribed period or pay the holders a penalty.  The Company did not file a registration statement on Form S-1 within the required timeframeany and has accrued the total penalty of approximately $205,000 as of June 30, 2019.  The Company is negotiating with certain holders of the Series A Convertible Preferred Stock to accept Series A Convertible Preferred Stock instead of cash as settlement of the penalty.    

Consultant Termination

On June 28, 2019, the Company terminated a consulting arrangement with a contractor providing investor relation services. The Company and contractor have been in discussions regarding the settlement of contract terms and services provided through June 28, 2019. The Company has accrued $195,000 as the best estimate of the cost to settle any potential dispute regarding the contract terms.

Note 10. Stockholders’ Equity

The December 31, 2018 common share and additional paid-in capital amounts have been restated to reflect the share exchange in connection with the Alliance acquisition of SCW FL Corp. and subsequent one-for-nineteen reverse stock split.

Transfer of Common Shares to Consultants

On or about February 1, 2019, the Company’s founder and CEO as well as the President, transferred an aggregate of approximately 1,379,000 and 144,000 common shares, respectively to certain consultants of the Company, of which approximately 983,000 and 144,000 common shares  were sold to consultants in exchange for promissory notes.  The Company accounted for these share transfers as stock-based compensation expense based upon the Black-Scholes model as if these were stock option grants made byall claims again the Company. The Company used the following inputshad previously accrued $195,000 in the Black-Scholes option pricing model, expected lifeconnection with this consulting arrangement. The stock had a fair value of 5 years, risk-free interest rate of 2.51%, volatility 92% and dividend yield of 0%.  As a result,$5.76 per share.

Equity Financing

During May 2020, the Company recognized approximately $3.6 millionreceived $515,000 of stock-based compensation expense duringa committed $565,000 from the first quartersale of 2019 related to these share transfers.  Additionally, approximately 396,000135,527 shares of common stock were transferred by the founder and CEO to contractors for no consideration.  The Company accounted for these share transfers as stock-based compensation based upon the underlying common share(at a price of $0.23 as of the date of transfer.  The Company recognized $1.7 million of stock-based compensation expense related$3.80 per share) and warrants to these transfers during the first quarter 2019.

Stock Incentive Plan

In connection with Alliance’s acquisition of SCW FL Corp., the Company adopted Alliance’s Second Amended and Restated 2016 Equity Incentive Plan (“2016 Plan”). The 2016 Plan allows the Company to grant shares of the Company’s common stock to the Company’s directors, officers, employees and consultants. On January 30, 2019, the Alliance shareholders approved the amendment of the 2016 Plan to increase the number ofpurchase 169,409 shares of common stock, available for issuance thereunder to 3,000,000 shares of common stock, on a post-split basis.

On February 13, 2019, the Board of Directors of the Company granted an aggregate of 425,000 restricted stock units (“RSUs”) under the 2016 Plan, of which an aggregate of 325,000 were granted to management and vest quarterly over the next three years, and of which 100,000 were issued to a consultant and vest quarterly over one year. Upon the effectiveness under the Securities Act of a registration statement on Form S-8 with respect to the shares covered by the 2016 Plan, these RSUsvest in twelve equal quarterly installments, commencing on the grant date of February 13, 2019 and had a grant date fair value of $2.7 million.The Company also granted an additional 525,000 RSUs which are subject to performance vesting, of which an aggregate of 225,000 were issued to our management and of which 300,000 were issued to a consultant.Additionally, the board of directors awarded stock options under the 2016 Plan to each of the four independent board members to acquire an aggregate of 53,572 shares of the Company’s common stock and to an employee to acquire 25,000 shares. The stock options have a term of five years,at an exercise price of $6.49$4.00 per share, vest quarterly over four quarters beginningshare. As of June 30, 2020, the full amount has not been received and the shares have not been issued. The $515,000 received through June 30, 2020 is included in equity financing within current liabilities on the grant date of February 13, 2019 and had a grant date fair value of $431,000. The Company determined the fair value of the stock options using the Black-Scholes model with the following inputs, expected life 10 years, risk-free interest rate 0.25%, dividend yield 0%, expected volatility 90%.unaudited condensed consolidated balance sheet.

 

On June 28, 2019, the Company terminated the aforementioned consultant and reversed the stock-based compensation expense recognized during the first quarter 2019 totaling $162,250 as the consultant had not vested in any of the restricted stock units.

26

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)Stock Incentive Plan

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of June 30, 2019 and for the six months ended are:June 30, 2020 were:

 

Reflective of one-for-nineteen reverse stock split

  Warrant Grants  Stock Option Grants  Restricted Stock Units 
  Number of shares subject to warrants  Weighted-
average exercise price per share
  Number of shares subject to options  Weighted-
average exercise price per share
  Number of shares subject to restricted stock units  Weighted-
average exercise price per share
 
Balance at December 31, 2019  1,311,916  $8.80   338,595  $3.94   630,303  $           - 
Granted  100,000   4.80   -   -   2,300,845   - 
Exercised  (584,907)  5.70   (105,028)  4.28   (41,667)  - 
Cancelled/Forfeited  -   -   -   -   (475,000)  - 
Balance at June 30, 2020  827,009  $10.51   233,567  $7.16   2,414,481  $- 
Exercisable at June 30, 2020  827,009  $10.51   233,567  $7.16   189,500  $- 

 

  Warrant Grants  Stock Option Grants 
  Number of
Shares
Subject to
Warrants
  Weighted-Average
Exercise Price Per
Share
  Number of
Shares
Subject
to Options
  Weighted-Average
Exercise Price
Per Share
 
Balance at December 31, 2018  236,825  $27.84   135,023  $7.70 
Granted  1,112,220  $5.67   53,572   6.49 
Exercised  (11,075)  5.51   -   - 
Cancelled/Forfeited  (26,054)  5.51   -   - 
Balance at June 30, 2019  1,311,916  $9.88   188,595  $7.35 
Exercisable at June 30, 2019  1,311,916  $9.88   188,595  $7.35 

As of June 30, 20192020 and December 31, 2018,2019, the total unrecognized expense for unvested stock options and restricted stock awards, net of actual forfeitures, was approximately $4.1 million$3,885,115 and $0,$3,236,292, respectively, to be recognized over a three-yearone to three year period for restricted stock awards and one year for option grants from the date of grant.

27

SCWorx Corp.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Stock-based compensation expense isfor the three and six months ended June 30, 2020 and 2019 was as follows:

 

  Three Months
Ended June 30,
  Six Months
Ended June 30,
 
  2019  2018  2019  2018 
Stock-based compensation expense $220,540  $-  $5,850,373  $-
  For the three months ended  For the six months ended 
  June 30,  June 30, 
  2020  2019  2020  2019 
Stock-based compensation expense $1,988,883  $220,540  $2,356,547  $5,850,373 

 

Stock-based compensation expense categorized by the equity components isfor the three and six months ended June 30, 2020 and 2019 was as follows:

 

 Three Months
Ended June 30,
  Six Months
Ended June 30,
  For the three months ended For the six months ended 
 2019 2018 2019 2018  June 30,  June 30, 
 2020  2019  2020  2019 
Common stock $1,988,883  $147,012  $2,356,416  $404,896 
Stock option awards $73,528  $-  $122,547  $-   -   73,528   -   122,547 
Common stock  147,012   -   404,896   - 
Transfer of common stock by founders to contractors  -   -   5,322,930   -   -   -   -   5,322,930 
 $220,540  $-  $5,850,373  $- 
Total $1,988,883  $220,540  $2,356,416  $5,850,373 

 

28

Note 9. Net Loss per Share

  

SCWorx Corp.Basic net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock outstanding during each period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding option grants.  

Notes to Condensed Consolidated Financial Statements

(Unaudited)The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

  For the three months ended  For the six months ended 
  June 30,  June 30, 
  2020  2019  2020  2019 
Stock options  233,567   188,595   233,567   188,595 
Warrants  827,009   1,261,968   827,009   1,261,968 
Total common stock equivalents  1,060,576   1,450,563   1,060,576   1,450,563 

 

Note 11. Net Loss per Share10. Related Party Transactions

 

Basic net loss per shareIncluded in accounts payable are amounts due to officers of the Company in the amount of $170,505.

Note 11. Subsequent Events

Complaint Filed Against the Company

On July 9, 2020, James Schweikert, the former COO of the Company, filed a complaint against the Company alleging breach of his employment agreement with the Company. Mr. Schweikert is computed by dividing net loss forseeking enforcement of the period by the weighted average sharesseverance provisions of commonhis employment agreement, stock outstanding during each period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock, common stock equivalentsawards and potentially dilutive securities outstanding during each period.other unspecified compensatory damages. The Company usesis currently in discussions to settle this matter.

Issuance of Restricted Stock Units

On August 6, 2020, the treasury stock methodCompany issued 140,000 RSUs in satisfaction of approximately $90,000 in accounts payable. If the Company pays all or a portion of this payable prior to determine whether there isSeptember 5, 2020, a dilutive effectpro rata portion of outstanding option grants. 

29

SCWorx Corp.

Notesthe RSUs would be returned to Condensed Consolidated Financial Statements

(Unaudited)the Company.

 

The following securitiesOn August 10, 2020, Timothy A. Hannibal accepted the appointment of President and COO of the Company. In connection with his appointment, the Company issued Mr. Hannibal 200,000 RSUs, of which 100,000 vest in ninety days, and the remaining 100,000 vest in six equal quarterly installments, commencing February 7, 2021 and every 90 days thereafter, until fully vested. 99,226 RSUs were excluded from the computationissued to Mr. Hannibal in satisfaction of diluted net loss per share$153,800 of indebtedness for the periods presented because including them would have been anti-dilutive:services, and are fully vested. 307,581 RSUs were issued to him compensation for services and vest in three equal semi-annual installments commencing October 7, 2020.

  Three Months
Ended June 30,
 
  2019  2018 
Stock options  188,595    
Warrants  1,261,968    
Total common stock equivalents  1,450,563    

  Six Months
Ended June 30,
 
  2019  2018 
Stock options  188,595    
Warrants  1,261,968    
Total common stock equivalents  1,450,563    

 

30

  

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes included in “ItemItem 1, - Financial“Financial Statements” of Part I of this Form 10-Q. In addition to our historical unaudited condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs which involveinvolves risk, uncertainty and assumptions. Our actual results could differ materially from those discussed in suchthe forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Form 10-Q.

 

Nature of BusinessCorporate Information

 

SCWorx, LLC (n/k/a SCW FL Corp.) (“SCW LLC”) was a privately held limited liability company which was organized in Florida on November 17, 2016. On December 31, 2017, SCW LLC acquired Primrose Solutions, LLC (“Primrose”), a Delaware limited liability company, which became its wholly-owned subsidiary and focused on developing functionality for the software now used and sold by SCWorx Corp. (the “Company” or “SCWorx”). The majority shareholdersinterest holders of Primrose were shareholdersinterest holders of SCW LLC and based upon Staff Accounting Bulletin (“SAB”) Topic 5G, the technology acquired has been accounted for at predecessor cost of $0. To facilitate the planned acquisition of SCWorx (the “Acquisition”) by Alliance MMA, Inc., a Delaware corporation (“Alliance”), on June 27, 2018, SCW LLC merged with and into a newly-formed entity, SCWorx Acquisition Corp., a Delaware corporation (“SCW Acquisition”), with SCW Acquisition being the surviving entity. Subsequently, on August 17, 2018, SCW Acquisition changed its name to SCWorx Corp. On November 30, 2018, the Companyour company and certain shareholdersof our stockholders agreed to cancel 6,510 shares of common shares.stock. In June 2018, the Companywe began to collect subscriptions for common stock. From June to November 2018, the Companywe collected $1.25 million$1,250,000 in subscriptions and issued 3,125 shares of common stock to new third-party investors. In addition, on February 1, 2019, (i) SCWorx Corp. (f/k/a SCWorx Acquisition Corp.) changed its name to SCW FL Corp. (to allow Alliance to change its name to SCWorx Corp.) and (ii) Alliance acquired SCWorx Corp. (n/k/a SCW FL Corp.) in a stock- for- stockstock-for-stock exchange transaction and changed Alliance’s name to SCWorx Corp., which is the Company’sour company’s current name, with SCW FL Corp. becoming our subsidiary. On March 16, 2020, in response to the Company’s subsidiary.COVID-19 pandemic, SCWorx established a wholly-owned subsidiary, Direct-Worx, LLC.

   

Our principal executive offices are located at 590 Madison Avenue, 21st Floor, New York, New York, 10022. Our telephone number is (844) 472-9679. The Company also had a lease in Greenwich, CT which was set to expire in March 2020 and is now month-to-month.

In this Quarterly Report, the terms “SCWorx,” the “Company,” “we,” “us” and “our” refer to SCWorx Corp., a Delaware corporation, unless the context requires otherwise. Unless specified otherwise, the historical financial results in this Annual Report are those of our company and our subsidiaries on a consolidated basis.

Our Business

 

SCWorx is a leading provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers and big data analytics for the healthcare industry.

 

SCWorx has developed and markets health information technology solutions and associated services that improve healthcare processes and information flow within hospitals. SCWorx’s software platform enables healthcare providers to simplify, repair, and organize its data (“data normalization”), allows the data to be utilized across multiple internal software applications (“interoperability”) and provides the basis for sophisticated data analytics (“big data”). SCWorx’s solutions are designed to quickly and accurately improve the flow of information quickly and accurately between the existing supply chain, electronic medical records, clinical systems, and patient billing functions. The software is designed to achieve multiple operational benefits such as supply chain cost reductions, decreased accounts receivables aging, accelerated and more accurate billing, contract optimization, increased supply chain management and cost visibility, synchronous charge description masterCharge Description Master (“CDM”) and control of vendor rebates and contract administration fees.

 


SCWorx empowers healthcare providers to maintain comprehensive access and visibility to an advanced business intelligence that enables better decision-making and reductions in product costs and utilization, ultimately leading to accelerated and accurate patient billing. SCWorx’s software modules perform separate functions as follows:

 

virtualized item master file repair, expansion and automation;
virtualized Item Master File repair, expansion and automation;

 

CDM management;
CDM management;

 

contract management;
contract management;

 

request for proposal automation;
request for proposal automation;

 

rebate management;
rebate management;

 

big data analytics modeling; and
big data analytics modeling; and

 

data integration and warehousing.
data integration and warehousing.

 

SCWorx continues to provide transformational data-driven solutions to manysome of the finest, most well-respected healthcare providers in the United States. The Company’s clientsClients are geographically dispersed throughout the country. The Company’sOur focus is to assist healthcare providers with issues that they have pertaining to data interoperability. SCWorx provides these solutions through a combination of direct sales and relationships with strategic partners.

 

SCWorx’s software solutions are delivered to its clients within a fixed term period, typically a three-to-five-year contracted term, where such software is hosted in SCWorx data centers (Amazon Web Service’s “AWS” or RackSpace) and accessed by such clientsthe client through a secure connection in a software as a service (“SaaS”) delivery method.

 

SCWorx currently sells its solutions and services in the United States to hospitals and health systems through its direct sales force and its distribution and reseller partnerships.

 

SCWorx, as a resultpart of the Acquisition, alsoacquisition of Alliance MMA, operates an online event ticketing platform focused on serving regional MMA (“mixed martial artsarts”) promotions. Due to the relative size of the ticketing business and how information is reported to the Company’s chief operating decision maker, the Company includes such ticketing business as part of its SaaS business reporting unit.

 

SaaS BusinessWe currently host our solutions, serve our customers, and support our operations in the United States through an agreement with a third party hosting and infrastructure provider, RackSpace. We incorporate standard IT security measures, including but not limited to; firewalls, disaster recovery, backup, etc. Our operations are dependent upon the integrity, security and consistent operation of various information technology systems and data centers that process transactions, communication systems and various other software applications used throughout our operations. Disruptions in these systems could have an adverse impact on our operations. We could encounter difficulties in developing new systems or maintaining and upgrading existing systems. Such difficulties could lead to significant expenses or to losses due to disruption in our business operations.

  

In addition, our information technology systems are subject to the risk of infiltration or data theft. The Company’s SaaStechniques used to obtain unauthorized access, disable or degrade service, or sabotage information technology systems change frequently and may be difficult to detect or prevent over long periods of time. Moreover, the hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud or deception aimed at our employees, contractors or temporary staff. In the event that the security of our information systems is compromised, confidential information could be misappropriated, and system disruptions could occur. Any such misappropriation or disruption could cause significant harm to our reputation, lead to a loss of sales or profits or cause us to incur significant costs to reimburse third parties for damages.


Impact of the COVID-19 Pandemic

Our operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and the world. The New York and New Jersey area, where our company is headquartered, was at one of the early epicenters of the coronavirus outbreak in the United States. The outbreak has since spread to the rest of the country and is impacting new customer acquisition. We have been following the recommendations of local health authorities to minimize exposure risk for our team members since the outbreak.

In addition, our customers (hospitals) have also experienced extraordinary disruptions to their businesses and supply chains, while experiencing unprecedented demand for health care services related to COVID-19. As a result of these extraordinary disruptions to our customers’ business, our customers are currently focused on streamlining three coremeeting the nation’s health care needs in response to the COVID-19 pandemic. As a result, there is a significant risk that our customers will not be able to focus any resources on expanding the utilization of our services, which could adversely impact our future growth prospects, at least until the adverse effects of the pandemic subside. In addition, the financial impact of COVID-19 on our hospital customers could cause the hospital to delay payments due to us for services, which could negatively impact our cash flows.

We are endeavoring to mitigate these risks through the sale of personal protective equipment (“PPE”) and COVID-19 rapid test kits to the health care industry, including many of our hospital customers. Our Chief Executive Officer and employees have experience in the healthcare provider systems;industry and industry contacts, and a database of items designed to assist the healthcare industry in fulfilling its inventory demands.

On March 16, 2020, in response to the COVID-19 pandemic, we established a wholly-owned subsidiary, Direct-Worx, LLC to endeavor to source and provide critical, difficult-to-find items for the healthcare industry. Items have become difficult to source due to unexpected disruptions within the supply chain, financial and clinical enabling providers’ enterprise systemssuch as the COVID-19 pandemic. The products we have sought to work as one automated and seamless business management system. SCWorx offers an advanced software solution for the management of health care providers’ foundational business applications, empowering its customers to significantly reduce costs, drive better clinical outcomes and enhance such providers’ revenue. SCWorx supports the interrelationship between the three above-referenced core healthcare provider systems. This solution moves data from one application to another to drive supply cost reductions, optimize contracts, increase supply chain management cost visibility and control rebates and contract administration fees.

31

Revenues

The Company’s revenue is substantially derived from its SaaS based business.

Revenue is recognized upon the transfer of control of promised goods or services in an amount that reflects the consideration that the Company expects to receive in exchange for its products or services. 

The Company follows the accounting revenue guidance under Topic 606 to determine whether contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer.

The Company has identified the following performance obligations in its contracts with customers:source include:

 

1)data normalization: includes data preparation, product and vendor mapping, product categorization, data enrichment and other data related services.Test Kits — hawse have identified potential sources for Rapid Test Kits for COVID-19, but currently have no contracted supply of Rapid Test Kits.

 

2)(SaaS): generated from clients’ access of and usage of the Company’s hosted software solutions on a subscription basis for a specified contract term, which is usually annually. In SaaS arrangements, the client cannot take possession of the Company’s software during the term of the contract and generally has the right to access and use the software and receive any software upgrades published during the subscription period.

3)maintenance:PPE — Personal Protective Equipment (PPE) includes ongoing data cleansing and normalization, content enrichment, and optimization.

4)professional services: mainly related to specific customer projects to manage and/or analyze data and review for cost reduction opportunities.items such as masks, gloves, gowns, shields, etc.

 

A contract will typically include data normalization, SaaSThe sale of PPE and maintenance,rapid test kits for COVID-19 represent a new business for our company and is subject to the myriad risks associated with any new venture. We have for example encountered great difficulty in attempting to secure reliable sources of supply for both COVID-19 Rapid Test Kits and PPE including, 3M N95 masks, which are distinct performance obligationsthe preferred medical grade mask of US healthcare companies. Further, we have encountered shipping delays with regard to masks and are accounted for separately. The transaction priceother PPE, and significant quality related issues regarding N95 masks. In addition, regarding our sourcing of COVID-19 Rapid Test Kits, we have encountered significant shipping delays, as well as reduced quantities. In addition, we currently have no contracted supply of Rapid Test Kits. Consequently, there is allocatedno assurance as to each separate performance obligation onwhether we will be able to source a relative stand-alone selling price basis. Significant judgement is requiredreliable supply of COVID-19 Test Kits. We have yet to determinecomplete the standalone selling price for each distinct performance obligationsale of any COVID-19 rapid test kits. As of June 30, 2020, we had approximately 47,000 test kits and is typically estimated based on observable transactions when these services areapproximately 40,000 sampling kits in inventory. In addition, changes in FDA processes governing the sale of COVID-19 serology tests could have the effect of rendering the COVID-19 serology tests to be sold on a standalone basis. At contract inception, an assessment of the goods and services promisedby our company not saleable in the contracts with customers is performed andUnited States, which could have a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when the performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment atmaterial adverse effect on our company. There can be no assurance that time, the Company has transferred use of a good or service and the customer iswe will be able to direct the use of, and obtain substantially all the remaining benefitsgenerate any significant revenue from the goodsale of PPE products or service.rapid test kits.

 

The Company’s SaaS and maintenance contracts typically contain termination for convenience provisions that doWe have yet to complete the sale of any COVID-19 rapid test kits. Through the date of filing we have not include penalty terms and accordingly, are generally accounted for as month-to-month agreements. If it is determined thatgenerated any material revenue from the Company has not satisfied a performance obligation, revenue recognition will be deferred until the performance obligation is deemed to be satisfied.sale of PPE or rapid test kits.

 

Revenue recognition for the Company’s performance obligations are as follows:

Data Normalization and Professional Services

The Company’s data normalization and professional services are typically fixed fee. When these services are not combined with SaaS or maintenance revenues as a single unit of accounting, these revenues are recognized as the services are rendered and when contractual milestones are achieved and accepted by the customer.

SaaS and Maintenance

SaaS and maintenance revenues are recognized ratably over the contract terms beginning on the commencement date of each contract, which is the date on which the Company’s service is made available to customers.

The Company does have some contracts that have payment terms that differ from the timing of revenue recognitions, which requires the Company to assess whether the transaction price for such contracts include a significant financing component. The Company has elected to rely on the practical expedient that permits an entity to not adjust for the effects of a significant financing component if it expects that at the contract’s inception, the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. The Company does not enter into contracts whose terms permit customers to pay for the Company’s goods or services in excess of one-year from when such customers received the Company’s goods or services.

32

Results of Operations - Three and Six Months Endedthree months ended June 30, 20192020 and 20182019

 

RevenueOur operating results for the three month periods ended June 30, 2020 and 2019 are summarized as follows:

 

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Revenue  1,364,912   812,060   552,852   68%
  Three Months Ended    
  June 30,
2020
  June 30,
2019
  Difference 
          
Revenue $1,444,572  $1,364,912  $79,660 
Cost of revenues  950,334   1,293,738   (343,404)
General and administrative  3,358,267   2,372,385   985,882 
Other income  (885,773)  -   (885,773)
Benefit from income taxes  -   195,000   (195,000)
Net loss  (3,749,802)  (2,496,211)  (1,253,591)

 


Revenues

Revenue for the three months ended June 30, 20192020 was $1.4 million,$1,444,572, compared to revenue for the three months ended June 30, 2018, which was $812,000.2019 of $1,364,912. The increase in revenue is primarily related to revenue from the addition of four new multi-year customer contracts and monthly revenue from customers which were brought on in 2019 subsequent to the end of the second quarter. Given the disruption caused to our hospital customers by the COVID-19 pandemic, our second quarter was adversely impacted, and we expect the impact to continue into at least the third quarter of this year, if not longer. Customer retention includes monthly and annual recurring revenue that should not be significantly impacted by the pandemic. 

Operating Expenses

Cost of revenues

Cost of revenues were $950,334 for the three months ended June 30, 2020 compared to $1,293,738 for the same period in 2019. The decrease was primarily the result of fees related to new product development and programming incurred in the three months ended June 30, 2019 which was not present during the firstthree months ended June 30, 2020. This decrease was partially offset by an increase to our workforce. We do not expect to incur significant product development costs for the remainder of this year.

General and administrative

General and administrative expenses increased $985,882 to $3,358,267 for the three months ended June 30, 2020, as compared to $2,372,385 in the same period of 2019. Stock-based compensation increased $1,768,407 from the second quarter of 2019 data consulting projectsdue to additional RSUs issued during April 2020. Legal fees increased $128,397 compared to the prior period, due to a number of complaints filed against our company during the three months ended June 30, 2020. These increases were partially offset by a $524,603 decrease in accounting and auditing fees due to purchase accounting completed during the second quarter of 2019, totaling $305,000,2020, a license renewal of $50,000,$146,309 decrease in travel expenses due to COVID-19, and monthly maintenance revenue from new customers froma $110,502 decrease in SEC and proxy expenses due to Nasdaq listing fees incurred during 2019. We expect legal fee expenses to remain high due to the thirdongoing litigation along with stock compensation expense. We are putting plans in place to attempt to reduce other general and fourth quarter 2018.administrative expenses.

Other Expenses

 

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Revenue  2,613,016   1,598,164   1,014,852   64%

We had other expense of $885,773 in the six months ended June 30, 2020 compared to $0 in the same period in 2019. Other expense in the first half of 2020 related to a loss on settlement of accounts payable of $885,773 due to the fair value of the shares issued in settlement being greater than the value of the accounts payable.

Net Loss 

For the three months ended June 30, 2020, we incurred a net loss of $3,749,802 compared to a net loss of $2,496,211 for the same period in 2019.

Results of Operations - six months ended June 30, 2020 and 2019

Our operating results for the six month periods ended June 30, 2020 and 2019 are summarized as follows: 

  Six Months Ended    
  June 30,
2020
  June 30,
2019
  Difference 
          
Revenue $2,568,399  $2,613,016  $(44,617)
Cost of revenues  1,783,534   2,264,947   (481,413)
General and administrative  4,798,545   9,000,324   (4,201,779)
Other income  (885,773)  441,335   (1,327,108)
Benefit from income taxes  -   -   - 
Net loss  (4,899,453)  (8,210,920)  3,311,467 

Revenues

  

Revenue for the six months ended June 30, 20192020 was $2.6 million,$2,568,399, compared to revenue for the six months ended June 30, 2018, which was $1.6 million.2019 of $2,613,016. The increaseslight decrease in revenue is primarily relatedwas partially due to revenue from the addition of four new customer contractsone-time sales during the first quarter of 2019, data consulting projects completed during the second quarter of 2019 totaling $305,000, a license renewal of $50,000, and monthly maintenance revenue from new customers from the third and fourth quarter 2018.

Expenses

Cost of revenue

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Cost of revenue $815,788  $729,131  $86,657   12%

Cost of revenue increased $87,000 to $816,000 for the three months ended June 30, 2019 comparedthat were not present during the six months ended June 30, 2020. Given the disruption caused to $729,000 forour hospital customers by the same period in 2018. The increase is relatedCOVID-19 pandemic, the first half of our year has been adversely impacted, and we expect the impact to additional consulting costs related to data consulting projects incontinue into at least the secondthird quarter of 2019.this year, if not longer. Customer retention includes monthly and annual recurring revenue that should not be significantly impacted by the pandemic.


Operating Expenses

 

Cost of revenues

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Cost of revenue $1,604,658  $1,522,356  $82,302   5%

 

Cost of revenue increased $82,000 to $1.5 millionrevenues were $1,783,534 for the six months ended June 30, 2019,2020 compared to $1.5 million$2,264,947 for the same period in 2018.2019. The increase is related to additional consulting costsdecrease was primarily the result of fees related to new customersproduct development and programming incurred in 2019.the six months ended June 30, 2019 which was not present during the six months ended June 30, 2020. This decrease was partially offset by an increase to our workforce. We do not expect to incur significant development costs for the remainder of this year.

 

General and administrative

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
General and administrative $2,372,385  $88,514  $2,283,871   2,580%

 

General and administrative expenses increased $2.3 milliondecreased $4,201,779 to $2.4 million for the three months ended June 30, 2019, compared to $89,000 for the same period in 2018. Salary and wages increased $510,000, as the Company hired additional executives in February 2019 in connection with the Acquisition, added our Chief Operating Officer during the second quarter 2019 and the Company accrued $195,000 to settle a potential dispute with a contractor that the Company terminated on June 28, 2019. Stock-based compensation expense increased $221,000 related to employee, director, and non-employee equity awards, $250,000 related to the penalty associated with the company not filing a registration statement on Form S-1 as required by the securities purchase agreement, dated as of December 18, 2018, between Alliance and the purchasers thereto (the “Preferred SPA”), accounting and auditing costs increased $695,000 related to the various required regulatory filings, technical accounting and valuation work related to the Acquisition. Legal fees increased $254,000 related to the Acquisition and various corporate matters, U.S. Securities and Exchange Commission (“SEC”) related expenses increased $95,000, travel increased $159,000 mainly related to sales opportunities, insurance increased $51,000 as the Company made adjustments to various policies, information technology supplies increased $9,000, amortization increased $9,500 and investor relations expenses increased $7,000.

We do not expect to incur further late fees related to certain requirements of our Series A Convertible Preferred Stock.

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
General and administrative $9,000,324  $224,030  $8,776,294   3,918%

General and administrative expenses increased $8.8 million to $9.0 million$4,798,545 for the six months ended June 30, 2019,2020, as compared to $224,000$9,000,324 in the same period of 2019. Stock-based compensation decreased $3,493,825 from the second quarter of 2019 due to shares that were transferred during the first quarter of 2019 to non-employee consultants by our CEO and a former significant shareholder. This decrease was partially offset by stock-based compensation of $1,988,883 during April 2020 related to the issuance of additional RSUs. Accounting and auditing fees decreased $589,503 due to purchase accounting completed during the six months ended June 30, 2019. SEC and proxy expenses decreased $239,934 due to Nasdaq listing fees incurred during the first half of 2019. Travel expenses decreased $134,770 due to COVID-19. These decreases were partially offset by a $260,781 increase in payroll and taxes due to additional people hired during 2019 and 2020 and health insurance fees for contract labor, a $189,030 increase in commissions due to a new relationship with a group purchasing organization, and a $187,642 increase in legal fees due to complaints filed against our company during the first half of 2020. We expect legal fee expenses to remain high due to the ongoing litigation along with stock compensation expense. We are putting plans in place to attempt to reduce other general and administrative expenses.

Other income (expense)

We had other expense of $885,773 in the six months ended June 30, 2020, compared to other income of $441,335 in the same period of 2019. Other expense in the first half of 2020 related to a loss on settlement of accounts payable of $885,773 due to the fair value of the shares issued in settlement being greater than the value of the accounts payable. In the prior period, there was a gain on the fair value of convertible note receivable of $410,055 and a gain on the fair value of warrant asset of $55,000. Additionally, interest expense was $23,720 during the six months ended June 30, 2019.

Net Loss

For the six months ended June 30, 2020, we incurred a net loss of $4,899,453 compared to a net loss of $8,210,920 for the same period in 2019. Salary and wages increased $765,000 as the Company hired additional executives in February 2019 in connection with the Acquisition, added our Chief Operating Officer during the second quarter 2019 and the Company accrued $195,000 to settle a potential dispute with a contractor that the Company terminated on June 28, 2019. Stock-based compensation expense increased $5.9 million related to employee, director, and non-employee equity awards and from the transfer of shares of our common stock from our CEO and former significant shareholder to non-employee consultants, $250,000 related to the penalty associated with the company not filing a Form S-1 as required by the Preferred SPA, accounting and auditing costs increased $950,000 related to the various required regulatory filings, technical accounting and valuation work related to the Acquisition. Legal fees increased $323,000 related to the Acquisition and various corporate matters, SEC related expenses increased $280,000, travel increased $194,000 mainly related to sales opportunities, insurance increased $81,000 as the Company made adjustments to various policies, information technology supplies increased $31,000, amortization increased $16,000 and investor relations expenses increased $18,000 offset by a $15,000 decrease in lease expense.

We do not expect to incur further stock-based compensation expense related to stock transfers by our founder or significant shareholder. However, we do expect stock-based compensation expense related to employee and non-employ equity awards to increase.

 

ResearchLiquidity and DevelopmentCapital Resources

 

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Research and development $477,950     $477,950   100%

Going Concern

 

Research and development expense increased $478,000 to $478,000 for the three months endedAs of June 30, 2019, compared to $0 for the same period2020, we had a working capital deficit of 2018. The increase is related to product development costs for product extensions leveraging our existing large data array technology.  

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Research and development $660,289     $660,289   100%

Research$2,164,960 and development expense increased $660,000 to $660,000 foraccumulated deficit of $17,693,926. During the six months ended June 30, 2019,2020, we had a net loss of $4,899,453 and used $1,000,995 of cash in operations. We have historically incurred operating losses and may continue to incur operating losses for the foreseeable future. We believe that these conditions raise substantial doubt about our ability to continue as a going concern. This may hinder our future ability to obtain financing or may force us to obtain financing on less favorable terms than would otherwise be available. If we are unable to develop sufficient revenues and additional customers for our products and services, we may not generate enough revenue to sustain our business, and we may fail, in which case our stockholders would suffer a total loss of their investment. There can be no assurance that we will be able to continue as a going concern.

As of the date of this report, we have only limited cash on hand, and we are experiencing negative cash flows from operations. Consequently, we need to raise additional capital in the near term to fund our operations and the implementation of our business plan.

On May 5, 2020, the Nasdaq Stock Market informed the Company that it had initiated a “T12 trading halt,” which means the halt will remain in place until the Company has fully satisfied Nasdaq’s request for additional information. This trading halt was lifted on August 10, 2020.

On May 5, 2020, we obtained a $293,972 unsecured loan payable through the Paycheck Protection Program (“PPP”), which was enacted as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES ACT”). The funds were received from Bank of America through a loan agreement pursuant to the CARES Act. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act and used for payroll costs, rent, mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven provided that (a) we use the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. While the full loan amount may be forgiven, the amount of loan forgiveness will be reduced if, among other reasons, we do not maintain staffing or payroll levels or less than 60% of the loan proceeds are used for payroll costs. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan. 


During May 2020, we received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share.

In connection with the Class Action and derivative claims and investigations described in Item 1. Legal Proceedings of this Quarterly Report on 10-Q, we are obligated to indemnify our officers and directors for costs incurred in defending against these claims and investigations. Because we currently do not have the resources to pay for these costs, our directors and officers liability insurance carrier has agreed to indemnify these persons even though the $750,000 retention under such policy has not yet been met. Ultimately, we will be obligated to pay the amount of the retention to the extent of actual settlement and defense costs, which payments could have a material adverse effect on the Company.

As of June 30, 2020, we had a working capital deficit of $2,164,960, compared to $0a deficit of $1,768,834 as of December 31, 2019. The $396,126 increase in the same period of 2018. The increase is related to product development costs for product extensions leveraging our existing large data array technology. 

33

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Other income            

Other incomeworking capital deficit was zero for both periods.

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Other income $465,000     $465,000   100%

Other income increased $465,000 to $465,000 for the six months ended June 30, 2019, compared to $0 in the same period of 2018. The increase is mainly relateddue primarily to an increase in contract liabilities of $770,625 and funds received for equity financing of $515,000 (included within current liabilities). These increases were partially offset by an increase in prepaid expenses and other assets of $681,471, and an increase in inventory of $558,119.

Based on our current business plan, we anticipate that our operating activities will use approximately $260,000 in cash per month over the fair valuenext twelve months, or approximately $3,120,000. Currently we have limited cash on hand, and consequently, we are unable to fully implement our current business plan. Accordingly, we have an immediate need for additional capital to fund our operating activities.

In order to remedy this liquidity deficiency, we are actively seeking to raise additional funds through the sale of equity and debt securities, and ultimately, we will need to generate substantial positive operating cash flows. Our internal sources of funds will consist of cash flows from operations, but not until we begin to realize additional revenues from the convertible notessale of our products and warrants issued by Allianceservices. As previously stated, our operations are generating negative cash flows, and thus adversely affecting our liquidity. If we are able to secure sufficient funding in the near term to fully implement our business plan, we expect that our operations could begin to generate significant cash flows during early 2021, which should ameliorate our liquidity deficiency. If we are unable to raise additional funds in the first quarternear term, we will not be able to fully implement our business plan, in which case there could be a material adverse effect on our results of 2019. Weoperations and financial condition. 

In the event we do not expect further benefits as these assets were converted in connection with the closing of the Acquisition on February 1, 2019.

  Three Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Interest expense    $48,434  $(48,434)  100%

Interest expense decreased $48,000 to $0 for the three months ended June 30, 2019, compared to $48,000 in the same period of 2018. The decrease is related to notes being settled withgenerate sufficient funds from revenues or financing through the issuance of $1.9 millioncommon stock or from debt financing, we may be unable to fully implement our business plan and pay our obligations as they become due, any of Series A Convertible Preferred Stockwhich circumstances would have a material adverse effect on February 1, 2019our business prospects, financial condition, and thus no additional interest on such notes is accrued.

  Six Months Ended
June 30,
  Increase  % 
  2019  2018  (Decrease)  Change 
Interest expense $23,720  $90,057  $66,337   74%

Interest expense decreased $66,000results of operations. The accompanying financial statements do not include any adjustments that might be required should we be unable to $24,000 forrecover the six months ended June 30, 2019, compared to $90,000 in the same periodvalue of 2018. The decrease is mainly related to notes and accrued interest being settled with the issuance of $1.9 million of Series A Convertible Preferred Stock on February 1, 2019 and thus only one month of interest on such notes accrued in 2019 (January 2019).our assets or satisfy our liabilities. 

  

LiquidityBased on our limited availability of funds we expect to spend minimal amounts on software development and Capital Resourcescapital expenditures. We expect to fund any future software development expenditures through a combination of cash flows from operations and proceeds from equity and/or debt financing. If we are unable to generate positive cash flows from operations, and/or raise additional funds (either through debt or equity), we will be unable to fund our software development expenditures, in which case, there could be an adverse effect on our business and results of operations.


Cash Flows

 

Our operations have historically generated negative cash flows, Consequently, our primary source of cash has been from the issuance of notes and collections on customer trade receivables.

  Six Months Ended June 30, 
  2019  2018 
Consolidated Statements of Cash Flows Data:        
Net cash (used in) provided by operating activities $(3,941,722) $635,131
Net cash provided by (used in) investing activities  4,912,081   (767,670)
Net cash provided by financing activities  287,548   301,225 
Net increase in cash $1,257,907  $168,686 

34

  

Six months ended

June 30,

 
  2020  2019 
       
Net cash used in operating activities $(1,000,995) $(3,941,722)
Net cash provided by investing activities  -   4,912,081 
Net cash provided by financing activities  847,542   287,548 
Change in cash $(153,453) $1,257,907 

 

Operating Activities

 

Cash used in operating activities was $3.9 million$1,000,995 for the six months ended June 30, 2020, mainly related to the net loss of $4,899,453 and an increase of $655,346 in prepaid expenses related to deposits for PPE. This was partially offset by stock-based compensation of $2,356,547, the loss on settlement of accounts payable of $885,773, an increase in contract liabilities of $770,625 related to customer repayments on long-term SaaS agreements, and net changes in accounts payable and accrued liabilities of $530,501.

Cash used in operating activities was $3,941,722 for the six months ended June 30, 2019, mainly related to the net loss of $7.8 million,$8,210,920, an increase of $641,000$640,541 in accounts receivable mainly related to data consulting completed and invoiced in June 2019, an increase in prepaid assets of $15,000$14,746 due to prepayments on insurance and our lease right to use asset, a decrease in accounts payable and accrued liabilities of $138,000$452,579 related to payments made on payable balances related to the Acquisition and operating expenses of SCWorx offset by a $95,000$95,482 increase in customer contract liabilities related to customer prepayments on long-term SaaS agreements, non-cash stock-based compensation of $5.9 million$5,850,373 related to the transfer of shares of common stock from our founders and founder/CEO and Presidenta former significant shareholder to non-employee contractors and equity awards to our management team and board of directors, and $586,000$586,405 of non-cash gains on warrants and convertible note assets with Alliance.

  

Cash provided by operatingInvesting Activities

We had no investing activities was $635,000 for the six months ended June 30, 2018, mainly related to the net loss of $238,000, an increase in accounts receivable of $153,000 related to timing of customer payments, offset by an increase of $761,000 in accounts payable, mainly related to deposits on common stock subscriptions and timing of vendor payments, and an increase of $266,000 in contract liabilities related to customer prepayments on long-term SaaS agreements.

Investing Activities2020.

 

Cash provided by investing activities was $4.9 million$4,912,081 for the six months ended June 30, 2019, related to $5.4 million$5,441,437 cash acquired as part of the Acquisition, offset by funding of$199,549 in advances due to a stockholder and founder in January 2019, of $200,000, advances on convertible notes receivable from Alliance of $215,000, and capital asset acquisitions totaling $115,000.$114,807.

 

Cash used in investing activities was $768,000 for the six months ended June 30, 2018, related to advances on a loan with a Company stockholder.

Financing Activities

 

Cash provided by financing activities was $288,000$847,542 for the six months ended June 30, 2019, primarily related to2020. This consisted of $515,000 proceeds from equity financing, $293,872 of proceeds from a loan payable, and $38,570 of proceeds from the exercise of warrants.

Cash provided by financing activities was $287,548 for the six months ended June 30, 2019. This consisted of proceeds from our notes payable with a significant Stockholder and former officer of $120,000, sale of Series A Convertible Preferred Stock totaling $100,000, and cash from the exercise of common stock warrants of $68,000.$67,548.

  

Cash provided by financing activities was $301,000 for the six months ended June 30, 2018, related to proceeds from our note with a significant stockholder and former officer of $856,000, offset by a $554,000 investment in convertible notes receivable with Alliance.

We do not expect any further advances from the significant shareholder\former officer, nor investments in convertible notes with Alliance.

Off-Balance Sheet Arrangements

 

As of June 30, 20192020 and December 31, 2018,2019, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

35

Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see Part II, Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recent Accounting Pronouncements

Refer to Note 3 - Summary of Significant Accounting Policies in the notes to our unaudited condensed consolidated financial statements for a full description of recent accounting pronouncements, including the respective expected dates of adoption.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.


Item 4.Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Management conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act, as of June 30, 2019,2020, the end of the period covered by this Form 10-Q, as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our Chief Executive Officer and Interim Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures.Disclosure Controls. Accordingly, even effective disclosure controls and proceduresDisclosure Controls can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our Chief Executive Officer and Interim Chief Financial Officer havehas concluded that, due to deficiencies in the design of internal controls and lack of segregation of duties, our Disclosure Controls were not effective as of June 30, 2019,2020, such that the Disclosure Controls did not ensure that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Management Report on Internal Controls over Financial Reporting

 

Our management has identified material weaknesses in our internal controls related to deficiencies in the design of internal controls effectiveness of financial reporting, disclosure controls and segregation of duties. Our managementManagement is workingplanning to meet with the Audit Committee of our board of directors to developdiscuss and work on remediation efforts which are expected to be remediated in the fourth quarter of 2019, until such time as our management is able to conclude that its remediation efforts are designed and operating effectively Management expects its remediation efforts will be completed during 2020. Our management is actively looking for a Chief Financial Officer along with other accounting and effective.finance personnel to assist in the remediation efforts.

 

Notwithstanding the foregoing, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that the unaudited condensed consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

36

 

We may in the future identify other material weaknesses or significant deficiencies in connection with our internal control over financial reporting. Material weaknesses and significant deficiencies that may be identified in the future will need to be addressed as part of our quarterly and annual evaluations of our internal controls over financial reporting under Sections 302 and 404 of the Sarbanes-Oxley Act of 2002.Act. Any future disclosures of a material weakness, or errors as a result of a material weakness, could result in a negative reaction in the financial markets and a decrease in the price of our common stock.

 

Changes in Internal Control over Financial Reporting.

 

During the quarter ended June 30, 2019, other than described above,2020, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 


PART II—II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

On March 29, 2019, Network 1 Financial Securities Inc. (“Network One”) servedIn conducting our business, we may become involved in legal proceedings. We will accrue a complaint against Alliance.   Network One allegesliability for such matters when it is probable that Alliance breached its obligation under its agreements with Alliance to indemnify Network One for certain costs that Network Onea liability has been incurred in connection withand the defense and settlementamount can be reasonably estimated. When only a range of possible loss can be established, the class action litigation previously instituted against Alliance and Network One.  This class action litigation has since been resolved, as previously disclosedmost probable amount in the Company’s Annual Report on Form 10-Krange is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for the fiscal year ended December 31, 2019, filed with the U.S. Securitiesa litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and Exchange Commission on April 1, 2019. Network One has demanded approximately $135,000 in payment of alleged damages.  The Company does not believe that it owes the amount demanded and intendsother directly related costs expected to vigorously defend against these claims.be incurred.

  

On December 19, 2018, the Company’s former CEO, Robert L. Mazzeo, who resigned on May 25, 2018, servedApril 29, 2020, a complaint against Alliancesecurities class action case was filed in the United States District Court for the Southern District of NY. Mr. Mazzeo allegesNew York against us and our CEO. The action is captioned Daniel Yannes, individually and on behalf of all others similarly situated, Plaintiff vs. SCWorx Corp. and Marc S. Schessel, Defendants.

On May 27, 2020, a second securities class was filed in the United States District Court for the Southern District of New York against us and our CEO. The action is captioned Caitlin Leeburn, individually and on behalf of all others similarly situated, Plaintiff v. SCWorx Corp. and Marc S. Schessel, Defendants.

On June 23, 2020, a third securities class was filed in the United States District Court for the Southern District of New York against us and our CEO. The action is captioned Jonathan Charles Leonard, individually and on behalf of all others similarly situated, Plaintiff v. SCWorx Corp. and Marc S. Schessel, Defendants.

All three lawsuits allege that he (i) was fraudulently induced to become theour company and our CEO of the Company and (ii) entered into an employment contractmislead investors in connection with the Company and that the Company breached such contract. Mr. Mazzeo seeks damages in excess of $500,000. The Company believes that the lawsuit is frivolous and violative of Rule 11 of the Federal Rules of Civil Procedure. The Company filed an answerour April 13, 2020 press release with respect to the sale of COVID-19 rapid test kits. The plaintiffs in these actions are seeking unspecified monetary damages. These class action lawsuits are still pending and the court is currently in the process of designating the lead plaintiff. Once the lead plaintiff is designated, we expect the court to order such plaintiff to file an amended and consolidated complaint, on February 5, 2019, and in addition to mounting a vigorous defense, filed counter claims against Mr. Mazzeo alleging breach of fiduciary duty. The Company does not believe that it oweswhich will consolidate the amount demanded and intendsactions. We intend to vigorously defend against these claims.

In August 2018, SCWorx settled a dispute with a former employee for $260,000, of which approximately $132,000 was paid in 2018 and the balance of $128,000 was accrued at December 31, 2018. The remaining balance was paid in January 2019. The employee had sued the Company in Massachusetts Superior Court for compensation under an employment agreement.

Disputed Contract Claim

As part of Alliance’s public offering of shares of its common stock and warrants in January 2018, Alliance issued warrants that contained a provision requiring Alliance to pay the warrant holders the Black-Scholes value of such warrants upon a fundamental transaction, as defined in the SPA . On August 20, 2018, Alliance entered into a Stock Exchange Agreement with SCWorx which, upon the closing of the Acquisition in February 2019, qualified as a fundamental transaction under such Warrants. The holders of such warrants had thirty days to notify SCWorx of the exercise of their rights under this provision, and two holders did so in the allotted time. The Company negotiated settlements with such warrant holders aggregating approximately $175,000 in fair value. During the quarter ended June 30, 2019, the Company issued 19,801 shares of common stock and approximately $55,000 in cash in connection with such settlement.

Preferred Stock Penalty

On December 18, 2018, Alliance closed the placement of the first round of Series A Convertible Preferred stock pursuant to the Preferred SPA. The terms of the Preferred SPA required SCWorx to register the shares of common stock on a registration statement on Form S-1 within a prescribed period and to pay the holders a cash penalty if such shares were not timely registered.  The Company did not file a registration statement on Form S-1 within the required timeframe and has accrued approximately $205,000 in cash penalties as of June 30, 2019.  The Company is negotiating with certain holders of the Series A Convertible Preferred Stock to accept additional shares of Series A Convertible Preferred Stock instead of cash penalty payments.    

Consultant Terminationproceedings.

 

On June 28, 2019,15, 2020, a shareholder derivative claim was filed in the Company terminatedUnited States District Court for the Southern District of New York against Marc S. Schessel, Charles K. Miller, Steven Wallitt (all of whom are current directors), and Robert Christie (a former director) (“Director Defendants”). The action is captioned Javier Lozano, derivatively on behalf of SCWorx Corp., Plaintiff, v. Marc S. Schessel, Charles K. Miller, Steven Wallitt, Defendants, and SCWorx Corp., Nominal Defendant. This lawsuit alleges that the Director Defendants breached their fiduciary duties to us, including by misleading investors in connection with our April 13, 2020 press release with respect to the sale of COVID-19 rapid test kits, failing to correct false and misleading statements and failing to implement proper disclosure and internal controls. The Plaintiff, on our behalf, is seeking an award of monetary damages to us, improvements in our disclosure and internal controls, and legal fees. The Director Defendants intend to vigorously defend against these proceedings. This derivative action is also still pending, and the plaintiff in such action has agreed to voluntarily stay the case until a contractruling on a motion to dismiss, which we intend to file in the securities class action case.

In connection with these actions, we may be obligated to indemnify our CEO and any of our officers or directors who incur any liability or expense incurred as a third-party contractorresult of serving at our company’s request in such capacity.

In addition, following the April 13, 2020 press release and related disclosures (related to COVID-19 rapid test kits), the Securities and Exchange Commission made an inquiry regarding the disclosures we made in relation to the transaction involving COVID-19 test kits. On April 22, 2020, the Securities and Exchange Commission ordered that trading in the securities of our company be suspended because of “questions and concerns regarding the adequacy and accuracy of publicly available information in the marketplace” (the “SEC Trading Halt”). The SEC Trading Halt expired May 5, 2020, at 11:59 PM EDT. We are fully cooperating with the SEC’s investigation and are providing investor relation services.documents and other requested information.

In April 2020, we received related inquiries from The CompanyNasdaq Stock Market and such contractorthe Financial Industry Regulatory Authority (FINRA). We have been fully cooperating with these agencies and providing information and documents, as requested. On May 5, 2020, the Nasdaq Stock Market informed us that it had initiated a “T12 trading halt,” which means the halt will remain in settlementplace until we have fully satisfied Nasdaq’s request for additional information. We continue to fully cooperate with Nasdaq and respond to Nasdaq’s information requests as they are issued. The T12 trading halt was lifted on August 10, 2020.

Also in April 2020, we were contacted by the U.S. Attorney’s Office for the District of New Jersey, which is seeking information and documents from our officers and directors relating primarily to the April 13, 2020 press release concerning COVID-19 rapid test kits. We are fully cooperating with the U.S. Attorney’s Office in its investigation.

On July 9, 2020, James Schweikert, the former COO of our company, filed a complaint against us in Ohio state court alleging breach of his employment agreement with our company. The case is captioned James Schweikert Vs. SCWorx Corp. Mr. Schweikert is seeking enforcement of the severance provisions of his employment agreement, stock awards and other unspecified compensatory damages. We are currently in discussions regarding the contract’s terms and the services provided through June 28, 2019. The Company has accrued $195,000 in order to settle this matter.

At this time, we are unable to predict the potential dispute with such contractor regarding the contract’s terms.duration, scope, or possible outcome of these investigations and lawsuits.


Item 1A. Risk Factors

 

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

  

None.Since the beginning of the three month period ended June 30, 2020, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported in a current report on Form 8-K, except as listed below.

 

37

On April 14, 2020, we issued 7,000 shares of our common stock to the holder of common stock warrants upon the exercise of 7,000 warrants for a cash payment of $38,570.

 

During April 2020, we issued an aggregate of 1,043,935 shares of our common stock to holders of our Series A Convertible Preferred Stock upon the conversion of an aggregate of 396,695 of such shares of Series A Convertible Preferred Stock.

During April 2020, we issued 321,155 shares of our common stock to holders of common stock warrants upon the cashless exercise of an aggregate of 520,925 warrants.

During May 2020, we issued an aggregate of 51,316 shares of our common stock to holders of our Series A Convertible Preferred Stock upon the conversion of an aggregate of 19,500 of such shares of Series A Convertible Preferred Stock.

During May 2020, we received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share.

During May 2020, we issued 26,034 shares of our common stock to holders of common stock warrants upon the cashless exercise of an aggregate of 56,982 warrants.

On June 24, 2020, we issued 80,000 shares of our common stock in full settlement of $195,000 of accounts payable.

The sales and the issuances of such shares of common stock described above were offered and sold in reliance upon exemptions from registration pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

 

Item 3. Default under Senior Securities

 

Not applicable.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

38

31

 

 

Item 6. Exhibits.

EXHIBIT INDEX

Pursuant to the rules and regulations of the SEC, we have filed certain agreements as exhibits to this Quarterly Report on Form 10-Q. These agreements may contain representations and warranties by the parties. These representations and warranties have been made solely for the benefit of the other party or parties to such agreements and (i) may have been qualified by disclosures made to such other party or parties, (ii) were made only as of the date of such agreements or such other date(s) as may be specified in such agreements and are subject to more recent developments, which may not be fully reflected in our public disclosure, (iii) may reflect the allocation of risk among the parties to such agreements and (iv) may apply materiality standards different from what may be viewed as material to investors. Accordingly, these representations and warranties may not describe our actual state of affairs at the date hereof and should not be relied upon.

 

(a)Exhibit #Exhibits.

 31.1Exhibit Description
3.1Certificate of Chief Executive Officer pursuantIncorporation, as amended February 1, 2019 (incorporated by reference to Rule 13a-14(a) underExhibit 3.1 to the Securities and Exchange Act of 1934, as amended.Company’s 10-K filed with the SEC on April 1, 2019)
   
3.3 31.2Certificate of Chief Financial Officer pursuantAmended and Restated By-laws (Incorporated by reference to Rule 13a-14(a) underExhibit 3.3 to the Securities and Exchange Act of 1934, as amended.Company’s Registration Statement on Form S-1 (File No. 333-213166) filed with the SEC on August 16, 2016)
   
10.2 32.1CertificateSupply Agreement with ProMedical Equipment Pty Ltd. Dated April 10,2020 (terminated April 29, 2020) (incorporated by reference to Exhibit 10.2 of Chief Executive Officer to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.Company’s 10-K filed with the SEC June 12, 2020)
   
10.3 32.2Purchase Order with Rethink My Healthcare, Inc (terminated April 23, 2020) (incorporated by reference to Exhibit 10.3 to the Company’s 10-K filed with the SEC June 12, 2020).
10.4CertificateSupply Agreement dated April 29, 2020 (name of supplier, unit price and total units redacted) (incorporated by reference to Exhibit 10.4 to the Company’s 10-K filed with the SEC June 12, 2020)) (terminated June 30, 2020).
10.5Service Agreement dated April 16, 2020 (identity of service provider redacted) (incorporated by reference to Exhibit 10.5 to the Company’s 10-K filed with the SEC June 12, 2020)
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(b) underSection 302 of the Securities and ExchangeSarbanes-Oxley Act of 1934, as amended.2002*
32.1Section 1350 Certification of the Chief Executive Officer*
32.2Section 1350 Certification of the Chief Financial Officer*
101 SCHXBRL Taxonomy Extension Schema Document
101 CALXBRL Taxonomy Calculation Linkbase Document
101 LABXBRL Taxonomy Labels Linkbase Document
101 PREXBRL Taxonomy Presentation Linkbase Document
101 DEFXBRL Taxonomy Extension Definition Linkbase Document

*Filed herewith

 

39


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 

 SCWORX CORP.
   
Date: August 14, 20192020By:/s/Marc S. Schessel
 Name: Marc S. Schessel
 Title:Chief Executive Officer
  (Principal Executive Officer)

 

Date: August 14, 2019By:/s/ John Price
Name:  John Price
Title:Chief Financial Officer
(Principal Financial Officer)
(Principal Accounting Officer)

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 40

EXHIBIT INDEX

Exhibit NumberDescriptionSCWORX CORP.
   
31.1Date: August 14, 2020By:Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*/s/ Timothy A. Hannibal
  
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*Timothy A. Hannibal
  
32.1Section 1350 Certification of the Chief Executive Officer *
32.2Section 1350 Certification of the

Interim Chief Financial Officer*

101.INSXBRL Instance Document*
101.SCH XBRL Taxonomy Extension Schema Document*
101.CALXBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFXBRL Taxonomy Extension Definition Linkbase Document*
101.LABXBRL Taxonomy Extension Label Linkbase Document*
101.PREXBRL Taxonomy Extension Presentation Linkbase Document*Officer

(Principal Financial Officer)

 

*Filed herewith

34

41